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Abstract 
CD8+ T cells can inhibit HIV-1 replication in infected CD4+ T cells in a non-cytolytic 
manner by suppressing transcription from the viral promoter. The factor mediating this response, 
referred to as CD8 Antiviral Factor (CAF), and its mechanism of action, are unknown. The 
overall aim of this project was to elucidate the mechanisms by which CAF mediates its HIV-1 
transcription suppressing effects. Towards this, we first studied the interaction of CAF with 
CD4+ target cells; then, investigated the signaling molecules involved in the process of viral 
transcription suppression; and thirdly, identified a region on the HIV-1 Long Terminal Repeat 
(LTR) promoter necessary for CAF-mediated transcription suppression. We used exosomes 
secreted by CD8+ T cells as a source of CAF to examine the interactions of CAF with its CD4+ 
target cells. Exosomes interacted with the cells at their surface, within 10 minutes of addition. 
However, maximal suppression of transcription was seen in the cells only 12 to 16 hours after 
addition. These results suggest the involvement of an intracellular signaling cascade and, 
possibly, secondary gene expression. Previous reports, using HVS-transformed CD8+ T cell 
lines, have shown the requirement for the intracellular signal transducer, STAT1, in CAF-
mediated viral transcription suppression. However, we found that the requirement for STAT1 in 
the suppressive process was seen only when CAF from transformed CD8+ T cells (CAFtransformed) 
was used. In contrast, CAF from primary CD8+ T cells (CAFprimary), from HIV-1 infected 
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 v 
patients, suppressed HIV-1 transcription in a STAT1-independent manner. Our investigations on 
the region of the viral promoter necessary for suppression showed the importance of the minimal 
promoter region of HIV-1 LTR. This 90bp region, containing 3 SpI sites and TATA box, was 
sufficient for transcription suppression to occur. Hence, our studies implicate a multi-pronged 
mechanism of CAF action on the LTR minimal promoter, and indicate major differences 
between CAF from transformed and primary CD8+ T cells.  
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PREFACE 
 
कमर्ण्येवा�धकारस्त ेमा फलेषु कदाचन। 
मा कमर्फलहेतुभूर्मार् ते सङ्गोस्त्वऽकमर्�ण॥ 
(Bhagavad Gita, Chapter 2:47) 
 
karmaNyEva aDhikArastE mA falEshu kadachan 
ma karmafalaheturBhuyam ma te sangostvakarmaNi 
 
Act not from an expectation of the fruit of the action.  
 
  
 
Or, in more practical terms, don’t think of the result when performing an experiment!  
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1.0  INTRODUCTION 
Human Immunodeficiency virus (HIV) is the defining epidemic of our age. In the thirty years 
since the discovery and description of acute immunodeficiency syndrome (AIDS), its etiological 
agent, HIV, has become the fastest spreading infectious agent. As of 2009, there are 33.3 million 
adults and 2.5 million children under the age of 15 infected with HIV in the world. In 2009, an 
estimated 2.2 million new cases of HIV-1 infection occurred [1].  The economic burden of HIV 
in the United States alone was estimated in 2006 at $36.4 billion, with $6.7 billion in direct 
medical costs [2] . Although there is no cure or preventive vaccine for HIV, great strides have 
been made in our understanding of the virus, its life cycle and its various interactions in the 
body.  This understanding has made the development of antiretroviral drugs targeting key viral 
proteins possible, thereby helping slow down the progression of the disease, reduce transmission, 
increase the lifespan of infected individuals and improve their quality of life.  
HIV is arguably the most investigated infectious organism. Intense research efforts have 
helped elucidate not only the virus and its interactions with its host cells, but also have 
uncovered many secrets of the human immune system, such as non-cytolytic antiviral responses 
of CD8+ cells, methods of intercellular communication between T cells, B cells and 
macrophages by the means of nanotubules and exosomes, genetic polymorphisms on MHC 
molecules that lead to increased or decreased susceptibility to viral infections and so on.  
 2 
For the rest of this introduction section, we shall take a look at the virus and its life cycle, 
its effects on various cells of the human body, followed by the different strategies of antiviral 
defense that are related to the Dissertation objectives .  
. 
1.1 THE HUMAN IMMUNODEFICIENCY VIRUS 
The isolation of a retrovirus from a patient with lymphadenopathy at the Pasteur Institute in Paris 
in 1983 provided the first hint that the causative agent of AIDS might be a retrovirus. Soon 
afterwards three labs around the world independently isolated the virus and gave it three different 
names: the virus isolated at Pasteur Institute at Paris was named lymphadenopathy-associated 
virus (LAV), the virus isolated at University of California at San Francisco was named AIDS-
associated retrovirus (ARV), and the virus isolated at the National Institutes of Health at 
Baltimore was named Human T-cell lymphotropic virus-III (HTLV-III). The name Human 
Immunodeficiency Virus (HIV) was recommended in 1986 by the International Committee on 
the Taxonomy of Viruses.   
 There are two types of HIV: HIV-1 and HIV-2. HIV-2 is associated with lower 
morbidity and longer incubation periods, although patients with HIV-2 also develop AIDS. HIV-
2 is thought to have arisen by interspecies transmission from its counterpart in sooty mangabeys 
(SIVsmm), while HIV-1 is thought to have arisen from chimpanzees (SIVcpz). HIV-1 strains can 
be classified into 3 groups: M (for Major), O (for Outlier) and N (non-M, non-O). Group M 
strains can be further sub-classified into 10 sub-types or clades (A to K).  
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The genome organization of HIV-1 is summarized in Figure 1. In addition to the three 
structural proteins present in all retroviruses, Gag, Pol and Env, HIV-1 has 2 regulatory proteins 
Tat and Rev and 4 accessory proteins, Nef, Vif, Vpr and Vpu (Vpx in HIV-2). The 9 proteins are 
coded by three, separate open reading frames (ORFs), as shown in Figure 1. The functions of 
these proteins are given in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Figure 1: The genome structure of HIV-1  
Taken with permission from the Los Alamos Database 
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Table 1-1: The proteins of HIV-1 and their functions 
Proteins of HIV 
Gag Group Antigen protein is cleaved into 6 smaller proteins, out of 
which p24 forms the capsid. Other cleaved products form the nucleocapsid 
(p6, p7), matrix (p17) and spacer peptides p1 and p2. 
Pol Polymerase protein is cleaved to form the reverse transcriptase 
(RT), protease (PR) and integrase (IN).  These proteins are responsible for 
converting the RNA genome into dsDNA, to cleave Gag, Pol and Env 
polyproteins and catalyze the integration of the dsDNA into the host 
genome, respectively.  
Env Env protein consists of 2 subunits: gp120 (also known as Surface or 
SU subunit) and gp41 (known as transmembrane or TM subunit). These 
subunits are crucial in mediating the fusion of the virus to the target cell and 
hence, viral entry into the cell 
Tat Tat is the one of the two regulatory proteins of HIV. Tat (Trans-
activator of transcription) interacts with the viral promoter and increasing the 
processivity of RNAPol II, driving transcription from the HIV LTR 
promoter.  
Rev Rev (Regulator of virion) protein regulates the export of singly 
spliced and unspliced viral mRNAs from the nucleus to the cytoplasm.  
Nef Negative Effector protein has many effects, both positive and 
negative, on viral replication. It decreases the expression of MHC Class I 
and CD4 molecules to inhibit super-infection; it also increases T cell 
activation and B cell dysfunctionality. 
Vpr Viral Protein R has a nuclear import sequence, and aids in the entry 
of the viral pre-integration complex into the nucleus from the cytoplasm. Vpr 
also affects the cell cycle of the target cell, by causing G2 arrest. Vpr induces 
neuronal apoptosis 
Vpu Viral Protein U enables viral release from the surface of infected 
cells by countering the action of the host restriction factor tetherin/BST2 
Vif Viral Infectivity Factor counters the action of the host restriction 
factor APOBEC3G and retains the integrity of the viral genome, thereby 
maintaining viral infectivity.  
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1.2 LIFE CYCLE OF HIV-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.1 Viral Entry 
HIV requires the protein CD4 as the receptor for its entry. In addition to CD4, the co-receptor 
proteins, CCR5, primarily found on the surface of macrophages, and CXCR4, found on the 
surface of CD4+T cells, are also required. HIV has long served as the prototype for viruses that 
infect by fusion at the plasma membrane. The gp120 subunit of the Env protein of the virus 
          Figure 2: The life cycle of HIV-1 
The life cycle of HIV-1: 3 out of the 5 key classes of antiretroviral drugs have been marked. (Taken with 
permission from Nature Publishing Group). The other main drug classes, not identified in this figure are 
entry/fusion inhibitors and integrase inhibitors. HIV-1 life cycle begins with entry mediated by gp120 and gp41, 
followed by uncoating and reverse transcription of the ssRNA genome into dsDNA. The viral protein integrase 
catalyzes the integration of the dsDNA into the host genome. Efficient transcription and translation enable the 
production of large numbers of viral proteins and genomes, which are packaged to assemble progeny virions 
 
 6 
makes contact with the CD4 molecule. The interactions between gp120, CD4 and the co-receptor 
molecule lead to a conformational change in the gp120. It is thought that these conformational 
changes on the gp120 expose the inner subunit of Env, gp41. Gp41, a transmembrane protein, 
embedded in the viral membrane, is also a fusion protein. It is likely that once gp41 is exposed, it 
inserts into the CD4+ target cell and mediates fusion between the virus and the target cell [3, 4] 
Recent evidence shows that HIV-1 can also be endocytosed rapidly, followed by fusion 
of the viral envelope with the endosomal membrane and mixing of the contents of the virus into 
the cellular cytoplasm. Thus, HIV appears to be able to use fusion at two sites: at the plasma 
membrane of the target cell and in the cytoplasm within the endocytotic vesicle [5]. 
1.2.2 Uncoating and Reverse Transcription  
An uncoating event follows fusion, wherein the contents of the viral capsid are released into the 
cytoplasm. These include the 2 strands of the RNA genome, and the proteins protease, integrase 
and reverse transcriptase.  
The reverse transcriptase (RT) enzyme catalyzes the conversion of ssRNA to dsDNA. 
This enzyme actually consists of 3 subunits: a reverse transcriptase domain, which converts 
ssRNA to ssDNA; a polymerase domain, which converts ssDNA to dsDNA; and an RNase H 
domain, which cleaves and degrades the original RNA template. Fidelity of the reverse 
transcription process is low, leading to high mutation rates of HIV in vivo. The dsDNA end 
product of RT, due to the complex process of reverse transcription, contains long terminal 
repeats at either end, which enable transcriptional regulation upon its integration into the host 
genome.  These long terminal repeats (LTR) are made of three regions: U3, R and U5. Once 
integration is complete and the retrovirus is in its ‘provirus’ form, the signals present on the LTR 
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sites lead to complex interactions between various cellular transcription factors, modulating 
transcription of the viral genome [4].  
1.2.3 Integration and Transcription 
Integration of the dsDNA product of the RT enzyme is catalyzed by the viral enzyme integrase 
(IN). Studies show a strong tendency of IN to insert the dsDNA product in sites of the host 
chromosome that are actively transcribed [6, 7]. Active nuclear import of the pre-integration 
complex takes place through the action of the viral protein Vpr, and host proteins such as 
transportin-SR2 and importin 7. Upon nuclear import, the host protein LEDGF/p75 tethers the 
preintegration complex onto the chromosome [8]. The viral protein IN catalyzes the steps of the 
DNA integration process and the formation of the provirus.  
Transcription from the LTR promoter of the integrated provirus is initially not efficient. The host 
cell’s transcription initiation complex containing RNA Pol II, TATA Binding Protein (TBP) and 
TBP-Associated Factors (TAFs) assemble at a site known as the Initiator of Small Transcripts 
(IST), a few basepairs downstream of the actual start site, and initiate transcription. The first few 
transcripts, though small in length, form the mRNA for the proteins Tat, Rev and Nef. Following 
protein translation, Tat enters the nucleus, to bind to a bulge-hairpin loop structure formed by the 
nascent mRNA, known as Transactivating Region or TAR. The binding of Tat to TAR recruits 
the host transcription factors pTef-b and Cyclin T1. Together this complex of proteins is able to 
phosphorylate the C terminus of RNA-Pol II, thereby increasing its processivity and enabling the 
process of transcription elongation. Phosphorylated RNA Pol II can now transcribe full length 
viral RNA molecules to form both mRNA and the ssRNA genomes of progeny virions. Since 
mammalian mRNAs are conditioned to be spliced, viral mRNAs that are either only singly 
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spliced or completely unspliced need to circumvent the splicing mechanism. The viral Rev 
protein is responsible for this process. It binds an element on the Env mRNA, known as the RRE 
(Rev Responsive Element) and promotes the egress of unspliced and singly spliced mRNA 
transcripts, gag, pol and env.  
1.2.4 Translation, Protein Synthesis and Egress 
Translation of the mRNA transcripts occurs in the cytoplasm. Gag, pol and env mRNAs are 
translated into polyproteins. Gag polyprotein is cleaved into capsid (p24), matrix (p17), 
nucleocapsid (p7) and p6 proteins, by the viral protease enzyme. Pol is cleaved into RT, protease 
and integrase enzymes, while Env is separated into gp41 and gp120 subunits. Gag assembly 
takes place at the plasma membrane. The special affinity for the plasma membrane by Gag is 
thought to be because of the high levels of the phospholipid PI(4,5)P2 found in this membrane, 
as opposed to any other cellular membrane [9, 10]. The acyl group of PI(4,5)P2 binds the MA 
(matrix) protein of the uncleaved Gag polyprotein, thereby anchoring Gag to the plasma 
membrane and orienting it in the right direction [11]. The viral RNA genomes that are to be 
packaged within the nucleocapsid are distinguished from viral mRNA by the presence of certain 
packaging signals, termed ψ(psi), located within the 5’ untranslated regions (UTRs) and/or 
upstream of the coding region of the gag gene [4, 12] . It is thought that the nucleocapsid (NC) 
on the Gag polyprotein binds to the RNA genomes via the ψ sequences and promotes their 
encapsidation. 
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1.3 NATURAL HISTORY OF HIV-1 INFECTION 
The course of HIV infection spans three broad stages, based on levels of plasma viremia/ CD4 
counts and clinical presentation: the acute stage, the asymptomatic chronic stage, the 
symptomatic chronic stage and the AIDS stage. 
The acute stage of HIV disease, occurring soon after infection, is accompanied by a burst 
of viral replication and corresponding depletion of CD4+ T cells. Although CD4+ T cell numbers 
in peripheral blood do not diminish significantly, there is a profound loss of resting memory 
CD4+ T cells in the gut associated lymphoid tissues (GALT), where the majority of CD4+ T cells 
reside (Figure 3)  [13-15].  
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Figure 3: Variation of total and peripheral CD4+T cells with time after HIV-1 infection.  
Decrease of total CD4+ T cells (dashed line) and peripheral blood CD4+ T cells (solid line) over time 
post HIV-1 infection (drawing not to scale). 
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In SIV models of acute infection in rhesus macaques, depletion of nearly 80% of total 
CD4+ T cells, by direct killing of the target cells by virus infection, and by virus-induced Fas 
mediated apoptosis, by 4 days post infection was observed [14, 16]. Thus, the acute phase of 
HIV infection is characterized by massive virus-induced cell death.  
Virus specific CD8+ T cells begin to appear about 3 to 4 weeks post infection (Figure 4). 
The importance of the CTL response in viral control has been well established with numerous 
reports showing a temporal association between the emergence of CTL responses and control of 
virus replication [17, 18], early emergence of CTL escape mutants [19, 20], and the resurgence 
in viral replication upon the removal of CD8+ T cells [21]. The first CD8+ T cell responses are 
directed against a narrow breadth of viral epitopes. Although this breadth increases in the chronic 
stage of the disease, no further viral control can be observed by CD8+ T cells, underscoring the 
importance and uniqueness of these first responses. Strong CD8+ T cell responses help establish 
a lower viral set point, thereby improving prognosis for the rate of disease progression [22]. 
While neutralizing antibodies are produced by B cells a few weeks-months after infection, their 
role in viral control is still controversial (more on this in later sections). The establishment of a 
reservoir of latently infected CD4+ T cells also occurs in this stage [23]. 
The chronic stage of HIV infection is characterized by very different dynamics of viral 
replication and immune cell turnover, as compared to the acute stage. Outwardly, the chronic 
stage appears “quiet”: viral loads are stably lower than they were in the acute phase and CD4+ T 
cell numbers rebound and are stable. However, in actuality, the chronic stage of HIV disease is 
characterized by a high level of generalized immune activation. Immediately following the loss 
in CD4+ T cell numbers, a vigorous, self-limiting immune activation is induced to increase the 
numbers of CD4+ T cells, and correspondingly, the number of target cells for virus infection 
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[15]. Preferential loss of Th17 CD4+ T cells in the gut leads to increased permeability of the 
intestines, resulting in microbial translocation from the gut to the peripheral blood, which, in 
turn, causes systemic activation of immune cells [24, 25]. There have been many lines of 
research in the recent past to indicate that immune activation is one of the key causes of HIV 
immunopathogenesis in the chronic stage [26-31]. African Green Monkeys and Sooty 
Mangabeys, natural hosts of SIV infection and in whom the disease is non-pathogeneic, also 
experience profound CD4+ T cell loss soon after infection, but do not exhibit the same degree of 
systemic immune activation soon afterward, as seen in humans or rhesus macaques [27, 30]. 
Immune activation leads to anergy and apoptosis not only of CD4+ T cells, but also of the other 
players of the immune system, notably CD8+ T cells and B cells [32-35]. The numbers of CD8+ 
T cells and B cells are relatively stable through much of the chronic phase of the disease, and 
begin to reduce around the latter stages of chronic infection, following irreplaceable losses in 
CD4+ T cell numbers. Dysregulated cytokine production also adversely affects multiple cell 
types. For example, TRAIL, a member of the TNF superfamily of cytokines, is produced in 
excess by antigen presenting cells upon HIV infection and leads to apoptosis of CD8+ T cells, 
monocytes and CD4+ T cells [36, 37].   
The stage of AIDS is characterized clinically by CD4+ T cell numbers of 200/mm3 or 
lower. In the absence of effective and appropriate co-stimulatory signals from CD4+ T cells 
antigen-specific CD8+ T cells undergo activation induced cell death (AICD) upon re-stimulation 
with antigen, although naïve CD8+ T cells have been noted to be able to respond to antigens [38]. 
Lack of CD4+ T cell help also leads to anergy in B cells. Opportunistic infections by organisms 
such as Pneumocystis carinii, cytomegalovirus (CMV), HHV8, candida and Cryptococcus are 
common [39].  
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Figure 4: Variation of plasma viremia and virus-specific CD8+ T cell numbers with time after infection with 
HIV-1.  
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Variation of virus-specific CD8+ T cells (dashed line) with plasma viremia (solid line) in different stages of HIV 
disease (drawing not to scale). 
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1.4 HIV-1 AND THE IMMUNE SYSTEM 
There are multiple effects of HIV-1 on the various cells of the immune system, and in turn, there 
are a variety of ways by which immune cells respond to HIV-1 infection. In this section, we shall 
take a brief look at the effect of HIV-1 on its major targets, which are the CD4+ T cells, dendritic 
cells (DCs) and monocytes/macrophages as well as on natural killer (NK) cells, B cells, and 
CD8+ T cells, as well as the immune responses mounted by each of these cell types to HIV-1 
infection. 
 
1.4.1 HIV and CD4+ T cells 
CD4+ T cells are one of the two main cell types that are infected by HIV-1. CD4+ T cells also are 
the major reservoir of HIV in the peripheral blood . HIV-1 infection of CD4+ T cells has many 
adverse effects not only on the cells themselves, but on the immune system as a whole. Infected 
cells show disrupted intracellular signaling, do not proliferate as well, are not activated in 
response to stimuli to the same extent, and cannot interact with antigen presenting cells with the 
same efficiency. Infected CD4+ T cells also undergo apoptosis faster. HIV-1 infects the various 
CD4+ T cell subsets, i.e. the naive cells, effector cells, effector memory cells and central memory 
cells, to different extents.  With the infection of the CD4+ T cells, other arms of the immune 
system are also adversely affected. Lack of CD4+T cell “help” results in dysfunction of CD8+ T 
cells and B cells. Figure 2 shows the various subsets of CD4+ T cells and is followed by a short 
summary of the effects of HIV on each of these subsets. 
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Figure 5: T cell subsets and their molecular markers 
 
Naïve CD4+ T cells: Exposure of naïve T cells to IL4, IL6, IL7 and IL15 in the thymus 
increases their susceptibility to infection. Although HIV-1 can enter these cells, often, conditions 
in the naïve cell are refractory to viral replication, with scanty resources, such as a sufficient 
supply of NTPs for reverse transcription, for crucial steps of the viral life cycle. A low supply of 
NTPs leads to accumulation of aborted reverse transcripts in the cell, which can cause apoptosis 
[40]. HIV-1 infection can also disrupts thymic structure, adversely impacting the process of T 
cell maturation and  development [41]. 
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Effector CD4 T cells: HIV preferentially infects HIV-specific CD4+ T cells [42]. Upon 
HIV infection, activated CD4+ T cells produce the most numbers of infectious progeny virions. 
HIV infection is associated with apoptosis of all effector T cell subsets. The different 
mechanisms contributing to this apoptosis include direct cytopathic killing of the infected cell, 
either by the virus itself or by HIV-specific CD8+ T cells. Secondly, virus infection induces 
syncytia formation between an infected cell expressing gp120 on its surface and an uninfected 
target cell expressing CD4+ and CXCR4 or CCR5. The cells thus fused die because of genomic 
instability. Third, upon productive infection, viral antigens are presented on MHC Class I to 
CD8+ T cells, causing activation of HIV-specific CD8+ T cells. Activated CD8+ cells cause 
apoptosis of the infected cells by injection of granzyme B and perforin. Fourth, T cells die by 
activation- induced-cell-death (AICD). This mechanism serves to limit the immune response by 
activated effector T cells. However, in HIV infection, there is generalized hyperactivation of T 
cells, as well as increased resistance of the infected cells to AICD-mediated apoptosis [43]. This 
results in the death of larger numbers of activated, though uninfected, T cells. Fifth, increased T 
cell turnover in the presence of constant antigenic stimulation and inflammation may cause T cell 
anergy. Finally, bystander T cells undergo apoptosis by the action of soluble Tat protein and the 
resulting enhanced activity of cyclin-dependent kinases [44]. 
Memory T cells: Memory T cells are preferentially targeted and massively depleted by 
HIV-1 infection [15]. Effector memory T cells are largely present in mucosal sites, such as the 
gut and cervix, and are among the first cells to undergo depletion in these sites soon after HIV 
infection, especially as they express CCR5 protein [45]. Central memory T cells (TCMs) 
undergo functional impairment upon HIV infection, with decreased cytokine secretion [46], and 
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decreased ability to differentiate into TEMs [47]. Resting memory cells constitute the main 
reservoir of latent viruses, leading to viral persistence after therapy. 
Regulatory T cells: The effect that HIV and Tregs have on each other is still under study. 
Tregs could have either a beneficial effect, by reducing T cell hyperactivation and bystander cell 
apoptosis, or a detrimental effect, by impairing HIV-specific immune responses and maintaining 
a viral reservoir [48].  
Th17 cells: Th17 cells numbers in the gut are significantly reduced after HIV infection. 
Since Th17 cells are useful in keeping control over bacterial infection, this preferential loss of 
Th17 cells is thought to cause microbial translocation from the gut [25]. 
 
1.4.2 HIV and Dendritic Cells (DCs): 
There are at least 2 major subsets of DCs, myeloid (mDC) and plasmacytoid (pDC), 
classified according to morphology and cytokine secretion [49]. mDCs secrete large quantities of 
IL12, an interleukin known to be important in the differentiation of T cells and in activation of 
natural killer cells and T cells [50-53]. pDCs secrete large quantities of IFNα [49, 54], a cytokine 
known for the antiviral responses in various cells. DCs express several receptors for detecting 
viruses, such as pattern recognition receptors (PRRs), which include Toll like receptors (TLRs) 
and C-type lectins [55]. Immature DCs which encounter the virus in peripheral tissues get 
activated and take up the virus, migrate to draining lymph nodes and trigger adaptive immune 
responses as well as promoting Natural Killer (NK) cell activation [56]. Activated DCs produce 
many cytokines, such as IL12, IL15, and IL18. Among these, IL12 is a potent inducer of Th1 
responses, which in turn activates the CD8+ cytolytic responses [57]. In addition, recognition of 
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viral RNA by TLR7 on DCs promotes the secretion of interferon alpha (IFNα). IFNα is known to 
have both positive and negative effects on the immune system during HIV infection. In the acute 
phase of HIV infection, IFNα recruits cytolytic NK cells, initiates adaptive immune responses 
and triggers intracellular antiviral pathways. However, it also acts as a chemotactic attractant to 
CD4+ T cells, which enter the mucosal sites and present easy targets for viral infection. In the 
chronic phase, IFNα can cause chronic immune activation of the cells, and also causes apoptosis 
of infected cells. 
HIV affects both mDCs and pDCs in many ways. The number of cells from both subsets of DCs 
is found to be significantly reduced in HIV positive individuals[58, 59], possibly because of 
increased apoptosis and/or necrosis of DC subsets upon fusion with HIV [60]. pDCs are also 
found to secrete lower levels of IFNα [61-63]. There is evidence to suggest that the ability of 
DCs to stimulate T cells is impaired, possibly because of dysfunctional co-stimulatory molecule 
expression [64-66]. Immature DCs are thought to have impaired maturation ability in the 
presence of HIV [67, 68]. A number of reports suggest that DCs transfer HIV-1 to CD4 T cells in 
lymph nodes, thereby bringing the virus to its target cells. Two types of DC-mediated HIV 
transmission to CD4+ T cells have been proposed: trans-infection and cis-infection. In trans-
infection, HIV-1 virions captured by the DCs are presented to CD4+ T cells across infectious 
synapses mediated by molecules such as ICAM-1 and DC-SIGN [69, 70]. A second method of 
trans-infection involves the uptake by CD4+ T cells of DC-secreted exosomes, which enclose 
HIV virions [71]. Cis-infection of DCs takes place by the productive infection of DCs by HIV-1, 
either after uptake of free virus, or from infected CD4 T cells, and the formation of progeny 
virions that can infect CD4+ T cells [72-75].  
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1.4.3 HIV and Macrophages 
Differentiation of monocytes to macrophages is a pre-requisite for the productive infection of 
these cells by HIV-1 [76-79], as the levels of Cyclin T1 and active pTEF-b are many fold higher 
in macrophages as compared to monocytes [80]. HIV-1 infection of monocytes and macrophages 
is characterized by alterations in cytokine production profiles, such as increases in IL1, IL6, IL8, 
TNF-alpha and other proinflammatory cytokines [81].  The process of phagocytosis is also 
disrupted by HIV-1 infection. This could be because of the disruption of various signaling 
process in macrophages [82]. HIV-1 infection of macrophages leads to their apoptosis. 
Sometimes, however, macrophages can become reservoirs for the virus, providing a protected 
environment for the latent virus to escape the effects of anti-retroviral therapy. Actively infected 
macrophages are thought to be the cause for the increasing viremia seen during the stage of 
AIDS, despite steadily dropping numbers of infected lymphocytes [77].  
1.4.4 HIV and Natural Killer (NK) cells 
Natural Killer (NK) cells are a key component of the innate immune system and respond to 
numerous microbes, fungi and parasites. Upon activation, NK cells release cytokines and 
chemokines that promote inflammatory responses, regulate cell growth, control hematopoiesis 
and influence the subsequent responses of the adaptive arm of the immune system [83]. One of 
the common evasion tactics employed by viruses is to down-regulate the expression of the MHC 
Class I molecule so that viral antigens may not be presented in high frequencies to CD8+ T cells. 
NK cells counter this action of viruses, by expressing a series of inhibitory NK receptors 
(iNKRs). iNKRs interact with MHC Class I molecules and inhibit the cytolytic activity of NK 
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cells. Loss or downregulation of MHC Class I molecules by viruses abolishes this inhibition of  
NK cells, which proceed to kill the virally infected cell through NK cytotoxicity receptors 
(NCRs) [84-86]. 
HIV infection has a number of effects on NK cell activity. The major effects of HIV are 
on the expression of iNKRs and NCRs, with iNKRs being overexpressed and NCRs being 
downregulated, by mechanisms as yet unknown [87, 88]. Additionally, NK cells are unable to 
express their usual complement of cytokines and chemokines, such as IFNγ and TNF-α. They 
also have a reduced ability to lyse target cells [83]. The HIV proteins Tat, Env and Vpr are 
known to dysregulate NK cell function in numerous ways. Tat has been shown to inhibit NK cell 
degranulation and secretion of lytic enzymes by blocking L-type Calcium channels in the cells 
[89]. Env inhibits NK cell survival and cytotoxicity [90]. Vpr has been shown to dysregulate 
cytokine signaling by NK cells, by inhibiting the secretion of IL12 and upregulating TGF-β [91], 
a cytokine that inhibits activation and proliferation of lymphocytes [92].  
Recent studies have found an important role for Natural Killer (NK) cells in viral control 
in the acute phase of HIV infection. While it is not known exactly how NK cells recognize HIV 
infected cells, different mechanisms have been proposed. NK cells can be activated by 
interaction with NK activating receptor ligands, such as NKG2D, which is expressed on the 
surface of infected cells. Infected cells can also present viral epitopes on their MHC Class I 
molecules, which allows for the activation of Killer cell Immunoglobulin-like Receptors (KIRs), 
which in turn activate NK cells. Antibodies bound on the surface of infected cells can activate 
NK cells through interactions with their Fc domains [93]. And finally, downregulation of MHC 
Class I molecules on infected cells can disrupt the binding of inhibitory KIRs, leading to NK cell 
activation [55].  
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1.4.5 HIV and B cells 
Recent studies with patient samples at time points immediately before, during and after 
the peaking of HIV plasma viral load in acute infection have shown that the first detectable B 
cell response can be seen as early as 8 days after detection of plasma virus. By 13 days post 
detection of plasma virus, the first HIV-specific antibody could be detected against gp41. Gp120 
specific antibodies were detected by 27 days.  However, while these first antibodies induced by 
the virus are capable of binding virions, they have little effect on the timing or magnitude of 
acute phase viremia [94]. 
Thus, the first antibody responses are non-neutralizing and directed against gp41 and then 
gp120. Neutralizing antibodies are seen several months after infection [94-96].  However, the 
role of broadly neutralizing antibodies in protection is still not determined. Some studies suggest 
that broadly neutralizing antibodies are not associated with control of viremia [97-99], while 
others suggest that they are likely to be key components of protection [100-102]. Numerous 
studies have shown that the development of a broadly protective, neutralizing humoral immune 
response, in rhesus macaques vaccinated with different strains of SIV, is a complex and lengthy 
process and can take as long as 6-8 months post infection [103].  
A crucial piece of evidence for the importance of humoral responses in protection against 
acquisition (though not viral control after infection) of HIV comes from the recent ALVAC-
prime recombinant Env gp12 boost RV144 phase III trial in Thailand. These results show a 31% 
vaccine efficacy in preventing acquisition of HIV, and the data implied that this protection is 
probably mediated by the levels of antibodies elicited early after vaccination [104].   High 
affinity/avidity antibodies against HIV gp120 are observed to be important in the prevention of 
vertical transmission of HIV [105].  
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CD4+ T cell infection by HIV results in profound and extensive immune activation and 
immaturity of B cells [35, 106]. Patients with HIV frequently are seen to have 
hypergammagobulinemia and many B cell malignancies [107, 108]. There may be many reasons 
for this. Activation of B cells could occur by the effects of TNFα, secreted by the infected T cells 
[109]. The HIV protein, Nef, is also known to stimulate B cells, both through direct interactions  
and through the induction of the cytokine IL6 in neighboring monocytes [110]. Nef can disrupt 
IgG2 and IgA class switching in B cells, by entering through nanotubule-like conduits formed by 
HIV infected macrophages [111]. Although B cells do not get directly infected by HIV, they 
have been shown to carry the virions on their surface through interactions of gp120 with CD4 
and  can transmit to T cells making them another reservoir for the virus and another mode of 
transmission of the virus to CD4+ T cells [112]. There is also evidence to indicate exhaustion and 
apoptosis of the memory B cell compartment, not restricted only to HIV-specific memory B cells 
[113]. 
1.4.6 HIV and CD8+ T cells 
CD8+ T cells are important for viral control. It has been observed that there is a temporal 
association between the emergence of HIV-specific CD8+ responses and a decrease in viral load 
in the acute phases of the infection [17, 18, 114, 115]. These first CD8+ responses are mounted 
against a small number of viral epitopes and are able to efficiently suppress viral replication [22]. 
Individuals who are able to mount strong CD8+ responses in the acute phase have lower viral set 
points, an accurate predictor of disease prognosis [116, 117]. Thus, CD8+ responses in the initial 
weeks after infection set the bar for the rate of progression of the disease in the future.  As the 
disease progresses, however, CD8+ T cells responses become more and more impaired due to 
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increasing dysregulation of the immune system by fast-evolving escape mutants. Even though 
the breadth and magnitude of CD8+ responses increases in the chronic phase of the infection, 
there is no further increase in protection or viral control seen [22, 38].  
CD8+ T cells, like CD4+ T cells, show chronic hyperactivation upon HIV infection. A majority 
of CD8+ T cells (80-90% of CD8+ T cells in peripheral blood), not just HIV-specific ones, 
express activation and proliferation markers, such as CD38 and Ki67, on their surfaces in the 
acute stages of the disease [32]. This generalized chronic activation and proliferation leads to 
exhaustion and anergy of CD8+ T cells, which begin to express receptors such as PDL1 
(Programmed Death Ligand I), before undergoing apoptosis [33, 34, 118]. CD8+ T cells also 
require co-stimulatory signals from CD4+ T cells  in order to mount efficient responses to 
chronic HIV infection and to establish memory [119, 120]. In the absence of this help from 
CD4+T cells, CD8+ T cells are unable to mount secondary responses to already-encountered 
antigen. They fail to proliferate and undergo activation-induced apoptosis when restimulated via 
the action of the death receptor TRAIL [121, 122].  CD8+ T cells can continue to secrete 
cytokines but are impaired in their cytolytic functions, due to inadequate maturation, as 
measured by expression of CD27 on the surface of these cells, and inadequate expression of 
perforin [123, 124]. CD8+ memory T cells are also affected by HIV infection. It has been noted 
that CD8+ memory T cells are predominately in a form that is a precursor to terminally 
differentiated cells, indicating that the maturation process in these cells is not yet complete. In 
contrast, CMV-specific memory CD8+ T cells were found to be in the fully mature, terminally 
differentiated state [125].  
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The antiviral responses of CD8+ T cells can be classified into cytolytic and non-cytolytic 
responses. The next sections will discuss each of these categories of responses briefly. 
 
1.4.6.1 Cytolytic CD8+ T cell Responses 
 
Cytolytic CD8+ T cells are, as their name suggests, those that lyse infected cells. CD8+ T cells 
sample the antigens presented on the HLA or MHC Class I molecules of antigen presenting cells, 
such as dendritic cells, with their T Cell Receptors (TCRs). The priming of CD8+ T cells by 
mature dendritic cells requires certain concomitant interactions: the interaction of the TCR with 
the antigen-loaded MHC Class I molecule on the DC and that of CD28 on the T cell with CD80 
or CD86 on the DC, in the presence of key cytokines such as IL12 and Type I interferons. For 
sustained activation and proliferation of antigen-specific CD8+ T cells, CD4+ T cell “help” is 
required.  Activated CD8+ T cells are loaded with granzymes, granulysin and perforins. When 
the activated, antigen-specific CD8+ T cell encounters its cognate epitope presented on the MHC 
Class I molecule of a virally infected cell, perforin is released, which forms pores on the target 
cell membrane, allowing the entry of granzymes into the cell. Granzymes are serine proteases. 
Upon entry into the cell, they cleave caspases and activate the caspase cascade, leading to 
apoptosis of the infected cell.     
 
The role of HLA molecules in cytolytic responses in HIV infection: A clear 
relationship exists between the HLA Class I alleles, the first CD8+ responses to HIV 
infection and the progression of the disease. Individuals heterozygous at HLA loci are 
capable of presenting a broader array of antigenic peptides, resulting in a broader and 
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more diverse CTL response [126, 127].However, the virus responds by mutating its epitopes so 
that it is no longer targeted by the HLA antigen presentation system. At a population level, 
individuals possessing rare HLA alleles are likely to have a selection advantage because the virus 
develops escape mutations (or other evasion tactics) to evade the most common HLA genotypes 
[128].  For example, it has been shown that CD8+ cells expressing the allele HLA-Class I B27 or 
B57 targeted against the p24 gag epitopes KK10 or TW10 respectively, are characterized by 
poly-functional capabilities, increased clonal turnover and superior functional avidity. These 
attributes of HLA-B27KK10 and HLA-B57TW10 CD8+ cells are associated with effective 
control of HIV-1 replication [129].  Such “super-genotypes” include the HLA alleles A1, A2, 
A3, A24, B7, B27, B58 etc. [128]. 
1.4.6.2 Non cytolytic CD8+ T cell Responses 
 
In contrast to the classical MHC restricted cytolytic responses, CD8+ T cells also exhibit non-
cytolytic responses mediated by secreted factors. Non-cytolytic CD8+ responses were discovered 
when researchers, seeking a reason for why some HIV infected individuals, known as Long 
Term Non Progressers (LTNPs), progressed to AIDS at a much slower rate than others, noticed 
that viral replication in infected cells was lower when the cells were cultured in the presence of 
CD8+ T cells from LTNPs. Yet, when the CD8+ cells were removed from the culture, viral 
replication rebounded to its original high levels, indicating that the infected cells had not been 
killed by the CD8+T cells. Thus, they reasoned, CD8+ cells were able to control viral replication 
in a non-cytolytic manner [21]. Since then, many non-cytolytic CD8 factors have been described. 
Among the more well known of these non-cytolytic secreted factors are the entry-inhibiting 
chemokines RANTES, MIP1alpha, MIP1beta and SDF1 [130]. RANTES, MIP1a and MIP1b 
 25 
compete for CCR5 and block the binding of R5 viruses to the co-receptor. X4 viruses are 
blocked by SDF1, which binds CXCR4 [131]. Other CD8+ non-cytolytic factors include ProT-
alpha (Prothymosin alpha) and the cytokine IL15, which inhibit HIV transcription in 
macrophages, but not CD4+ T cells [132] and enhance the non-cytotoxic abilities of CD8+ cells 
to suppress HIV replication respectively [133].  
One of the most important, yet enigmatic, non-cytolytic factors is the CD8 Antivial 
Factor (CAF). We will now focus on CAF in greater detail. 
 
 CAF suppresses transcription from the HIV Long Terminal Repeat (LTR) promoter. 
Early experiments suggested that suppression of viral replication was highest when there was 
cell to cell contact between the CD8+ cells and the infected CD4+ cells. However, culture 
supernatants of CD8+ cells could also suppress viral replication by significant levels [134]. Our 
lab recently published data showing that exosomes, which are 100nm vesicles secreted by cells, 
from CD8+ cells could also efficiently suppress viral replication [135]. Thus, it was inferred that 
CAF was present not only on the cell membrane of CD8+ T cells, but could also be secreted in 
the form of exosomes and might possibly even be cleaved off the surface of exosomes to be 
secreted into the supernatant. It can be inferred from its soluble nature that this factor does not 
require MHC restriction to function as an anti-HIV molecule, and indeed, experiments have 
proved its action in the absence of HLA compatibility [136]. The identity of CAF is still 
unknown. It has been shown by many groups that CAF does not identify with the cytokines or 
chemokines listed in Table 1-2  [130, 132, 137-147]. 
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The CAF-mediated inhibition of viral replication is found to correlate with the stage of 
the disease, and is usually most potent in the acute stages of the disease and may contribute to 
the establishment of the viral setpoint [148-151]. It is also observed in exposed-but-uninfected 
individuals and Long Term Non-Progressers, suggesting its importance in viral control [21, 147, 
IL1-IL13, IL15, Il16, IL18,  
TNF-alpha, TNF-beta, IFN alpha, IFN 
beta, IFN gamma,  
TGF beta, 
GMCSF, GCSF, RANTES, MIP-1alpha, 
MIP-1beta,  
Monocyte chemoattractant protein 
MCP-1, MCP-2, MCP-3,  
SDF-1,  
Growth regulated oncogene GRO-alpha 
and GRO beta,  
Lymphocyte Inhibitory Factor LIF-1,  
Interferon Regulated Protein IP-10,  
Granzymes A and B, Granulysin, 
Lymphotactin,  
alpha-defensins,  
Natural Killer cell enhancing factors 
(NKEF),  
Rnase,  
Protegrin,  
Histanins,  
Prothymosin alpha   
Table 1-2: List of chemokines and cytokines that do not identify with CAF 
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152]. CAF is also increased following antiretroviral therapy. CAF is   equally effective against 
various tropisms and clades of HIV-1, HIV-2, SIV, and FIV [21, 153-159]. The CD8+ cells that 
secrete CAF have not been found to be HIV-specific, and CD8+ cells from patients with CMV 
and EBV have been found to be equally effective. Characterization of the cells that produce CAF 
show that these cells have the activation markers  HLA-DR and CD38 [160, 161].  
 
The mechanism of action of CAF is also unknown. Some years ago, it was shown that 
culture supernatant from transformed CD8+ T cells could be used as a source of CAF, instead of 
obtaining primary CD8+ T cells and culturing them [162-164]. Using transformed CD8+ T cells 
and their culture media as a source of CAF, it was shown that the signaling molecule STAT1 was 
necessary for the process of suppression [165]. However, information about upstream and 
downstream interacting partners is as yet unknown, as is the exact mechanism of transcription 
suppression. 
Thus, we sought to determine the mechanism of action of CAF. 
 
 
 
 
 28 
2.0  OVERALL AIM AND SPECIFIC AIMS 
Overall aim: Our overall aim is to elucidate the mechanism of action of the CD8+ 
Antiviral Factor, which leads to the transcriptional suppression of HIV-1 Long Terminal Repeat 
promoter. 
 
Rationale and Hypothesis: Our preliminary studies on the kinetics of CAF action 
showed that target cells needed ~12-16 hour interval after the addition of CAF to provide 
maximum transcriptional suppression of HIV-1 LTR. This indicates a need for intracellular 
signaling and possibly production of an intermediate protein. Furthermore, we and others have 
shown that CAF action is mediated via the signaling protein STAT1. Since CAF has been shown 
to suppress gene expression from the viral promoter, , there may be one or more regions on the 
viral promoter that experience changes in protein binding, upon CAF addition which may 
ultimately lead to a reduction in transcription from the promoter. 
Therefore, we hypothesized that CAF triggers a signal cascade upon its interaction with 
target cells. This cascade of signals ultimately converges upon the integrated promoter of HIV-1, 
the Long Terminal Repeat (LTR), and causes changes in protein binding, which lead to 
suppression of transcription from the promoter. 
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2.1 SPECIFIC AIMS 
 
1. To study the interaction between CAF and its target cells 
 
2. To determine the intracellular signal cascade that is triggered in response to CAF that 
leads to transcription suppression. 
 
3. To determine the region on the LTR promoter that is crucial for the CAF mediated 
transcriptional suppression.  
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3.0  MATERIALS AND METHODS 
Primary cells, cell lines and virus stocks: Primary CD8+ T cells were isolated from the 
blood of nine therapy-naïve HIV-1 infected subjects, with CD4 counts greater than 400/uL from 
the Multicenter AIDS Cohort Study (MACS) with Institutional Review Board approval. CD8+ T 
cells were isolated using Dynal ™ immune-magnetic beads coated with antibody to CD8 protein, 
according to manufacturer’s instructions (Life Sciences Technologies, Carlsbad, CA). Isolated 
CD8+ T cells were grown in RPMI supplemented with 20% FBS, rIL2 (50U/mL, Roche 
Diagnostics), 25mM HEPES and the antibiotics Penicillin (100U/mL) and Streptomycin 
(100ug/mL) for 14 days. On day 14, cells were centrifuged at 300g and the resulting supernatant 
was used for further investigations. Primary CD8-negative T cells were prepared by immune-
magnetic depletion of CD8+ T cells from peripheral blood mononuclear cells (PBMCs) of 
uninfected subjects, as previously described [166].   CD8- negative PBMC were grown in the 
presence of phytohemaglutinnin for 3 days to activate and expand the CD4+ T cell population, 
followed by infection with the R5 primary viral isolate HIV015 as previously described [166]. 
The CD8+ T cell line, TG, was previously established by Herpes virus saimiri (HVS)-
transformation of CD8+ T cells from a chronically HIV-1 infected subjected from the MACS 
[167]. TZMbl cells were obtained from the NIH AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID from John C Kappes, Xiaoyun Wu and Transzyme Inc. 
HeLa-Tat cells were also obtained from the NIH AIDS Research and Reference Reagent 
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Program from William Haseltine and Ernest Terwilliger. The fibrosarcoma cell lines U1A, U2A, 
U3A, U4A, U6A, U3AR, G1A and G2A were a kind gift from Dr.George Stark (Cleveland 
Clinic, Cleveland, Ohio). 293T cells were obtained from the ATCC. TZMbl cells were grown in 
RPMI supplemented with 10% FBS and 25mM HEPES. The fibrosarcoma cell lines and 293T 
cells were cultured in DMEM, supplemented with 10% FBS, 2mM Glutamine and 1mM sodium 
pyruvate. The R5 primary viral isolate HIV-1 015 was obtained from the PBMC of HIV-1 
infected subjects enrolled in the MACS of University of Pittsburgh, as previously described 
[166, 167].  
Plasmid constructs:  Full length HIV LTR-CAT and the successive deletion constructs 
at EcoRV, BstNI, HaeIII and MnlI have been described in [168] and were a gift from Dr.Mario 
Estable of Ryerson University, Toronto, Canada. Wt-LTR-luciferase was created by amplifying 
the full length LTR with the primers ACCTCGAGTTAGTCAGCCATGTC (Fwd) and 
GTGAAGCTTTTCCTTAGCTCCTGAA (Rev), digesting the product with XhoI and HindIII 
and ligating it into the pGL4.10 (Promega, Madison, WI) cut with the same enzymes. The 
BstdelTAR construct was made by digesting the BstNI construct with KpnI and BglII, blunting 
the ends with Klenow fragment and then ligating the product with T4 DNA ligase.   SpI deletion 
mutants were created by overlapping PCR, using the specific DNA oligonucleotides and the 
corresponding primers listed in the Appendix section. For the point mutations, the mutations 
introduced to inactivate the SpI sites (underlined) are marked in bold, where G nucleotides were 
substituted by T: TTCGTGGCCTGTTCGGGACTGGTTAGTGGC. The oligonucleotide pairs 
and the corresponding primers used to create these constructs are also listed in the Appendix  
section.  For the deletion constructs, each pair of oligonucleotides was added, instead of template 
DNA, to the PCR mix and the reaction was cycled without primers for 5 times, with these 
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conditions: (94C, 2’30”; [94C-1’, 55C-1’, 72C- 1’45”]X5; 72C-10’), the primers were then 
added at a final concentration of 10uM and the tube was cycled for 25 cycles at the same cycling 
temperatures and times. The PCR product was purified, digested with HindIII and SacI and 
ligated, using T4 DNA ligase, to the BstdelTAR construct cut with the same enzymes. For the 
point mutations, each of the forward probes (K- P) was added along with Oligo 2, at a final 
concentration of 10mM and the corresponding reverse primer, at a final concentration of 1uM 
and PCR amplified for 10 cycles at the following conditions: (94C, 2’30”; [94C-1’, 55C-1’, 72C- 
1’45”]X10; 72C-10’). Primer a fwd was added at a final concentration of 1uM, and the reaction 
mixture was cycled 25 more times at the same conditions. The PCR product was purified, 
digested with HindIII and SacI and ligated, using T4 DNA ligase, to the BstdelTAR construct cut 
with the same enzymes. The sequences of all constructs were confirmed by sequencing with the 
primer 5’CGCTGGGCCCTTCTTAA, present on the luciferase gene.  
Antibodies and other reagents: Antibody to pSTAT1 (Y701 site) was obtained from 
Millipore (Billerica, MA). Antibodies to pSTAT3 and pSTAT5 (clone C11C5) were obtained 
from Cell Signaling Technology (Beverly, MA). 
Purification of exosomes. Exosomes were harvested from culture supernatants by 
adaptation of previously described methods involving serial centrifugation of the culture 
supernatant, followed by sucrose density gradient purification (18, 37). Culture fluid from TG 
cells or primary CD8+ T cells from HIV-1-infected subjects was harvested by centrifugation at 
300g for 10 min to deplete cells. Cell-free culture supernatant was subjected to serial 
centrifugations of increasing centrifugal force to derive supernatants and pellets at 800g for 30 
min, 6,000g for 30 min, 15,000g for 30 min, and 60,000g for 1 h, with all spins performed at 
4°C. The 15,000g pellet was then resuspended in HBSS and subjected to a discontinuous sucrose 
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density gradient centrifugation at 90,000g at 4°C through a 40% sucrose (1.14 g/ml) layer 
overlaid over a 60% sucrose (1.21 g/ml) cushion. After centrifugation, the membrane fractions 
banded over the 40% and 60% sucrose interfaces were removed, diluted in HBSS, and re-
centrifuged at 18,000g to purify the fractions. The membrane pellet was resuspended in HBSS 
and analyzed for the presence of exosomes. Exosome protein concentration was measured using 
a Bradford assay (Bio-Rad, Hercules,CA). 
Quantitative acute HIV-1 replication suppression assay: A quantitative acute HIV-1 
replication suppression assay was performed as previous described [166]. Briefly, CD4+ T cells 
acutely infected with HIV 015 were incubated in the presence of CAF for 5 days. On day 5, the 
extent of productive HIV-1 replication was assayed by measuring the concentration of 
extracellular p24 in culture supernatant using a standardized p24 ELISA kit (Perkin Elmer, San 
Jose, CA). MTT assays were also performed to measure cell viability, as previously described 
[169].    
Quantitative LTR promoter suppression assay: Assays of HIV-1 transcription 
suppression using the TZM-bl cell line were performed as previously described [135]. For all 
other target cell lines, HIV-1 LTR transcription suppression was assessed by transfection of the 
Wt-LTR-luc plasmid. Cells to be transfected were plated in antibiotic fee medium in 96 well 
plates at a concentration of 20,000 cells/well. Twelve hours after plating, CAF was added at 
either 10% vol/vol or 50% vol/vol concentrations depending on whether the source of CAF was 
transformed TG cells or primary CD8+ T cells from HIV-1 infected patients, respectively. 
Twenty four hours after the addition of CAF, cells were transfected with 1nng of Wt-LTR luc 
plasmid per well, using Lipofectamine LTX and Plus reagent (Life Sciences Technologies, 
Carlsbad, CA), according to manufacturer’s instructions. Twenty four hours after transfection, 
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cells were stimulated with 100ng/mL phorbolmyristoylacetate (PMA) for six hours and were 
assayed for both luciferase production by Bright Glo Luciferase Assay System (Promega, 
Madison, WI) according to manufacturer’s instructions, and cell viability by MTT assay, 
previously described [169].  
Confocal microscopy of exosome-cell interaction. TZM-bl or HeLa Tat cells were 
labeled, according to the manufacturer’s instructions, with PKH-67 (Sigma, Dekalb, MO), a 
lipophilic dye that binds cell membrane lipids by its long aliphatic tail. Cells were plated on 35-
mm uncoated dishes (type P35G-0-10C; Mattek Corp., Ashland, MA) at 75% confluence in 10% 
RPMI medium. Freshly harvested exosomes were quantified for protein concentration by 
Bradford’s assay (Bio-Rad Laboratories). Exosomes were then resuspended in HBSS to a 
total volume of 1 ml. A 1:250 dilution of the Cy5 dye (GE LifeSciences, Buckinghamshire, 
United Kingdom) was made, and 10 µl of the diluted dye was added to 30 _g of exosome 
protein. The incubation of dye with exosomes was performed at 4°C in the dark for 1 h. 
Following incubation, the exosomes were washed three times with HBSS and resuspended to a 
concentration of 1 to 1.5 µg/µl. Thirty micrograms of labeled exosomes was added to each dish 
of labeled cells, and incubation was carried out for 10 min or for 12 h at 37°C in the dark. 
Fixation was done at the required time points by 2% paraformaldehyde. Dishes containing fixed 
cells and exosomes were viewed under an Olympus Fluroview 1000 instrument. Images were 
analyzed using MetaMorph software. 
Depletion of Interferon gamma (IFNγ) and IFNγ ELISA: IFNγ ELISA kits were 
obtained from eBioscience (San Diego, CA). Samples to be depleted of IFNγ underwent three 
successive incubations on IFNγ antibody coated plates, beginning with an overnight incubation 
at 4C. Samples were removed, placed in new antibody-coated wells, and incubated for 2 hours at 
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room temperature. They were once again placed in new antibody-coated wells for a final 
overnight incubation at 4C, before being removed and evaluated for residual IFNγ by ELISA, 
according to manufacturer’s instructions. Control samples underwent the same incubations on 
rabbit IgG antibody-coated plates.  
Protein phosphorylation measurements: For time dependence experiments, CAF from 
TG cells was added at a 10% vol/vol concentration to 106 cells/mL of either TZMbl cells or 
acutely HIV-1 infected CD4+ T cells for different periods of time ranging from 1 minute to 24 
hours before cell lysis. For dose dependence experiments, CAF from TG cells was added, at 
concentrations ranging from 0.05% vol/vol to 15% vol/vol to  106 cells/mL of either TZMbl cells 
or acutely HIV-1 infected CD4+ T cells for 15 minutes before cell lysis. Cell lysates were 
aliquoted and stored in the presence of protease inhibitors until further use. Quantification of 
total and phosphorylated STAT1 was performed by Luminex ™ Map platform (Luminex, 
Austin, TX), using Mapmates ™ reagents (Millipore, Billerica, MA). Phosphorylation of the 
proteins Crk, FRS2, PLC-g2, Jak3, STAT3, p38 MAPK, JNK, Tec kinase, PI3K and IL15Ra was 
quantified using Epiquant ™ system (Millipore, Billerica, MA). Briefly, acutely HIV-1 infected 
CD4+ T cells, at a concentration of 106 cells/mL, were treated with 50% vol/vol IFNγ depleted 
or control CAF samples from primary CD8+ T cell culture supernatants for 10 min, 20 min, 12 
hours or 42 hours. Control cells treated with media only were included for each time point. cells 
were lysed, processed and digested according to the kit’s protocol. Digested lysates were then 
incubated with antibodies against the phosphorylated peptide-forms of the above mentioned 
proteins and analyzed by Luminex 1000 instrument. The phosphorylation of each protein was 
compared to that found in the media control and the fold change from the media control was 
calculated.  
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CAT and luciferase assays: 293T cells were plated at a concentration of 20,000 
cells/100uL in a 96 well plate. 24 hours after plating, 10% vol/vol of CAF from TG cells was 
added to the culture. Following an additional 24 hours, 1ng of the relevant plasmid was 
transfected into all cells, using Lipofectamine Plus (Invitrogen, Carlsbad, CA), according to 
manufacturer’s instructions. 24 hours following transfection, the cells were stimulated with 
100ng/mL phorbolmyristoylacetate (PMA) for 6 hours, after which they were lysed and the 
amount of CAT protein or luciferase was measured. CAT and luciferase protein expressions 
were quantified by CAT ELISA (Roche) and Bright Glo expression systems (Promega), 
respectively, according to manufacturer’s instructions. 
Western blots: Cell lysates were run on 10% SDS protein gels (Pierce Proteins, Rockford, IL), 
transferred on PVDF membranes (Millipore, Billerica, MA), blocked for 1 hour using 5% non fat 
milk and then probed for the expression of phosphorylated STAT1, STAT3 and STAT5. The 
secondary antibody used was goat anti rabbit antibody conjugated to horse radish peroxidase 
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4.0  STUDIES ON THE INTERACTIONS BETWEEN THE CD8 ANTIVIRAL 
FACTOR AND TARGET CELLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38 
4.1 ABSTRACT  
The CD8 Antiviral Factor (CAF) is a CD8+ T cell-secreted factor that is known to suppress HIV-
1 transcription. The identity and mechanism of action of CAF are unknown. We found that 
small, membrane-bound vesicles, named exosomes, secreted by CD8+ T cells contained high 
levels of CAF and were able to potently suppress HIV-1 transcription. We used these exosomes 
as a source of CAF to examine the interactions of CAF with its target cells. We observed that 
CAF-containing exosomes interacted with target cells at their surface within 10 minutes of 
addition. However, maximal suppression of transcription was seen in these cells only 12 to 16 
hours after addition. Exosomes could also be washed away within 5 minutes of addition to cells 
and would still produce significant suppression of LTR driven transcription, after a 12 to 16 hour 
incubation of the cells. These results indicate that HIV-1 transcriptional repression is triggered 
by one or more ligand-receptor interactions that occur upon membrane contact of exosomes with 
the target cells and the possible involvement of an intracellular secondary gene expression, 
Furthermore, exosome-mediated transcriptional suppression is dependent on STAT1 signaling 
pathway. 
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4.2 INTRODUCTION  
Previous studies on the nature of CAF found a dual presence of CAF, on the CD8 membrane, as 
well as culture supernatant. Although cell-to-cell contact between the CD8+ T cell and the target 
CD4+ cell resulted in maximal HIV-1 transcriptional suppression, CD8 culture supernatant could 
also suppress HIV-1 transcription efficiently [134]. Studies on the requirements of MHC 
compatibility between the CD8+ T cell and CD4+ target cell for CAF activity showed that CAF 
could act even when there was no MHC compatibility between the CD8+ T cells and the infected 
CD4+ T cells [136]. Thus, it appeared that CAF could be found in a membrane-associated form, 
on the CD8+ T cell surface, as well as in a soluble form in cell culture supernatant.  
 
One mechanism by which this could occur is by proteolytic cleavage of a membrane 
bound factor and release of the active form into the extracellular medium. However, experiments 
to test this proved inconclusive [170]. Another mechanism by which a surface bound protein 
might be secreted into the extracellular environment is through the process of endosomal 
trafficking. Cell surface proteins are continuously endocytosed by the cell into early endosomes. 
Early endosomes have many cellular fates [171, 172]. One possibility is that their contents might 
be degraded, following fusion of the endosomes to lysosomes. A second possibility is that the 
contents of the early endosomes may be recycled back to the surface [171]. A third possibility 
involves the fusion of many early endosomes into multi-vesicular bodies which then traffic back 
to the cell surface, and release the individual endosomes into the extracellular medium, in the 
form of “exosomes” [173, 174]. If CAF were indeed trafficked through endosomes from the cell 
surface, and secreted into the extracellular medium in the form of exosomes, it would not only 
still be membrane-bound, but it would also be present in the culture supernatant of CD8+ T cells, 
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thereby reconciling the various pieces of data showing that it were both membrane bound as well 
as soluble.   
 
 Exosomes are ~100nm-sized spherical, membrane-bound bodies secreted by cells either 
constitutively or upon activation. They are formed by the aggregation of endosomes inside multi-
vesicular bodies (MVBs). While most MVBs are degraded after fusion with lysosomes, some 
MVBs are recycled back to the cell surface and the endosomes contained within them are 
released in the form of small vesicles, known as exosomes. Exosomes are usually range from 
1.1-1.9g/cm3 in density. The protein composition of exosomes has been seen to be cell type 
specific, although some proteins, such as CD63, CD81 and other members of the tetraspanin 
family,  are found on all exosomes, regardless of the origin of the secreting cell [175]. Exosomes 
can be isolated from the culture supernatant of cells by a series of centrifugation steps, followed 
by density gradient purification. Our studies showed that CAF was present on the surface of 
exosomes and its suppressing activity could not be abolished even after the removal of peripheral 
proteins on the exosomes [135]. Thus, it appeared that the CAF protein complex was present as 
an integral membrane protein on the exosome surface.  
 
Since the identity of CAF is unknown, it was impossible to study its interactions with 
target cells. We therefore investigated transcriptional suppression by exosomes that carried CAF 
and tracked their interactions with target cells. Confocal microscopy indicated that interaction of 
exosomes with CD4+ target cells was limited to the cell surface, with no evidence for their 
internalization. Furthermore, our data indicate that an intracellular signaling mechanism is 
involved in exosome-mediated suppression of HIV-1 transcription. 
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4.3 RESULTS 
                               
                    
1. Exosomes from CD8+ T cells are able to suppress HIV-1 LTR driven transcription: It is 
known that CD8+ T cells and culture supernatant of these cells can exhibit CAF-mediated 
suppression of LTR-driven gene expression. Previous studies from our lab showed that 
membranes of transformed CD8+ T cells could suppress HIV-1 replication in infected 
primary CD4+ T cells by >90% [135]. We noticed that, in addition to the cell membrane, 
the fraction of the culture supernatant containing components of density between 1.14-
1.2g/cm3, could also suppress HIV-1 replication to nearly 100% (Figure 6A). This 
component contained 100nm-sized vesicles, known as exosomes (Figure 6B) 
  
                              
Figure 6:  Suppression of HIV-1 replication by CD8+ T cell culture supernatant fractions 
                                  
 
A B 
Culture supernatant from a transformed CD8 T cell line was serially centrifuged at 300g, 600g, 6000g 
and 15,000g. the 15,000g fraction was then purified on a sucrose density gradient. The fractions 
corresponding to 1-1.14g/cm3 and 1.14-1.21g/cm3 were isolated, purified and assayed for HIV-1 
replication suppressive activity (A). The fraction corresponding to 1.14-1.21 g/cm3 was observed 
under electron micrograph after purification (B). Figure used with permission from the Journal of 
Virology    
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We isolated these exosomes and characterized the proteins present in them. We found 
that although the exosomes were derived from CD8+ T cells, they did not express the 
CD8 molecule on their surface (Figure 7A), in contrast to the CD8+ T cell membrane 
(Figure 7B). However, CD63, a late endosome/lysosome marker, was readily detected on 
the exosome surface, indicating its origins in the endosomal compartment. Other 
tetraspanins, such as CD9 and CD81, were also enriched in the exosomes, as was the 
antigen presenting molecule, MHC Class II.  
 
 
Figure 7: Flow cytometry analysis of proteins on the exosome and CD8+ T cell membrane surface 
 
 
 
We determined whether exosomes secreted by these cells could also potently suppress 
LTR transcription. TZM-bl cells were exposed to CD8+ T cell-secreted exosomes for 24 
hours, after which they were infected with HIV-1 virus to stimulate gene expression of 
the reporter gene beta-galactosidase. We found that mRNA levels of beta-galactosidase 
A 
B 
Flow cytometry analysis was performed on exosome-coated beads (A) and transformed CD8 T cells (B) 
Unshaded areas represent the antibody isotype; shaded areas indicate specific fluorescence by the 
antibody labeled above each graph. Figure used with permission from the Journal of Virology [135] 
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were decreased when cells were treated with CD8 exosomes, compared to control (Figure 
8). This indicated that CAF on exosomes secreted by CD8+ T cells could potently 
suppress HIV-1 LTR driven reporter gene transcription. 
 
                                           
Figure 8: CD8+ T cell derived exosomes suppress transcription from the HIV-1 LTR.  
 
 
 
2. The suppression of LTR gene expression by exosomes from CD8+ T cells is time 
dependent: We next sought to determine if suppression of LTR-driven beta galactosidase 
expression by exosomes was dependent upon the duration of interaction between the cells 
and the exosomes. CD8+ T cell-derived exosomes were added to TZM-bl cells for various 
periods of time from 1 hour to 16 hours, following which cells were infected with HIV-1 
to stimulate HIV-1 LTR driven gene expression. The suppression of beta galactosidase 
was calculated in cells that received the exosome treatment, relative to control cells. We 
found that there was a high correlation between the duration of the exosome treatment 
 
Real-time RT-PCR measurement of LTR-activated β-galactosidase mRNA in TZM-bl cells in the 
absence or presence of exosomes. Values for β-galactosidase mRNA measurements were normalized by 
co-quantification of β2 microglobulin rRNA. Figure used with permission from the Journal of Virology 
[135] 
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and the degree of suppression of LTR gene expression. We also determined that maximal 
suppression (>85%) was found only after 12-16 hours of incubation post addition of 
exosomes to the cells (Figure 9).   
 
 
                                        
    Figure 9: Time dependent suppression of LTR-driven gene expression by CD8+ T cell derived exosomes  
 
 
 
3. Suppression by exosomes does not require the continued presence of exosomes: As 
shown above, a 12-16 hour time interval was required by cells post addition of exosomes 
to exhibit potent suppression of LTR driven transcription. We considered the possibility 
that this time interval could be due to the activation of some signaling pathways within 
the target cell in response to CAF, which might ultimately lead to transcription 
suppression of the LTR. Thus, if CAF was triggering some kind of signal response, 
Percentage suppression of LTR-driven beta galactosidase production in TZM-bl cells treated with CAF-
exosomes for increasing periods of time, n=3. Suppression was calculated by comparison with untreated 
controls. Figure used with permission from the Journal of Virology, [135] 
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continued presence of the CAF-containing exosomes probably would not be required for 
maximal suppression to be seen 12-16 hours later.   To test this possibility, we washed 
away CAF-containing exosomes at different time points after addition to TZM-bl cells, 
and let the cells incubate in the absence of exosomes for additional 12-16 hours and then 
challenged with HIV-1. Subsequently, we measured suppression of beta galactosidase 
expression. As shown in Figure 10, the level of gene expression in cells exposed to 
exosomes for 5 minutes are comparable to cells exposed to exosomes for 16 hr.  These 
results support the idea that CAF mediated suppression of HIV-1 may require synthesis 
of a secondary signal (protein) which may be ultimately responsible for transcriptional 
suppression of HIV-1 
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Figure 10: Continuous exposure of target cells to exosomes is not necessary for maximal suppression  
 
 
 
Suppression of LTR-driven beta galactosidase expression in TZM-bl cells treated with CAF-
containing CD8+ T cell exosomes for various periods of time ranging from 5 minutes to 960 minutes 
and then washed to remove the exosomes. 
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4. Interaction of CD8+ T cell exosomes with target CD4+ cells: The presence of an 
HIV-1 suppression factor on the extracellular surface of the exosomes as well as a time-
dependent induction for LTR promoter repression suggested the involvement of a CAF-
triggered signaling mechanism. We therefore sought to determine whether the exosomes 
directly interacted with the surface of target cells in their induction of HIV-1 suppression. 
We performed confocal microscopy using TZM-bl cells labeled with the lipophilic dye 
PKH67 to stain internal and external cell membranes. Exosomes were labeled with Cy5, 
a dye that covalently binds to the primary amine group of proteins. The Cy5-labeled 
exosomes were incubated with PKH67-labeled cells at 37°C in the dark for various times, 
and three-dimensional confocal microscopy was performed following fixation. After only 
10 min of coincubation, exosomes were found to concentrate at the cell surface, limiting 
their localization only to the periphery of TZM-bl cells (Figure 11, left panel). After 12 h 
of co-incubation, a time by which near-maximal HIV-suppressive activity was detected 
(Figure 9), the Cy5-labeled exosomes were still limited to the periphery of TZM-bl cells 
(Figure 11, right panel). No evidence for internalization of exosome membrane was 
found at 12 hr. This seemed to imply that the exosomes do not enter the cells, and the 
CAF on the exosomes interacts with the target cells at their surface.       
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Figure 11: Interaction between exosomes and target cells is restricted to the cell surface 
 
 
 
5. CAF from CD8+ T cell derived exosome signals via STAT1: Data presented above 
indicate that CAF mediated transcriptional suppression may involve intracellular 
signaling, leading to secondary gene expression.  Reports by other groups, using CD8 
culture supernatant, had indicated that the signaling molecule, STAT1, was involved in 
the process of suppression. We determined the role of STAT1 in the process of 
transcriptional suppression by CAF-containing exosomes from CD8+ T cells. For this 
purpose, we utilized two fibrosarcoma cell, the STAT1-deficient U3A cell line and the 
constitutively STAT1-expressing U3AR cell line, both derived from the parental 2fTGH 
fibrosarcoma cell line. U3A and U3AR cells were incubated in medium only or medium 
supplemented with HIV-1-suppressing exosomes for 10 h. After incubation, all cells were 
liposome-transfected with an HIV-1 LTR-CAT gene reporter plasmid followed by 
mitogen induction of the LTR with PMA. After an 8-h PMA stimulation, intracellular 
CAT protein concentration was measured by ELISA. We observed no HIV-1 suppression 
Interaction between Cy5 labeled (red) exosomes on the surface of TZM-bl (green) cells at 10 minutes 
(left panel) and 12 hours (right panel) post addition of exosomes to cells.  Images were taken by 
Olympus 1000 Floview microscope, after fixing the cell. Figure used with permission from the Journal 
of Virology, [135] 
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in STAT1-deficient U3A cells, but found 61% HIV-1 suppression in STAT1-expressing 
U3AR cells (Figure 12). This indicated that STAT1 was necessary for CAF-mediated 
suppression.   
 
                              
                                           
     Figure 12: Requirement for STAT1 in CAF-mediated HIV LTR transcriptional suppression.  
 
 
 
6. Exosome fractions from culture supernatants of primary CD8 T cells can also suppress 
HIV- transcription: The HIV-1 suppression studies described above were conducted 
using Herpes virus saimiri (HVS)-transformed CD8+ T cells. To confirm that the 
suppressive effects seen with the exosomes from transformed CD8+ T cells were not an 
artifact of the transformation process, we cultured primary CD8+ T cells from 2 therapy-
naïve HIV-1 infected patients and isolated partially purified exosomes from the culture 
medium. Our results showed that both cell membrane as well as exosome fractions from 
Suppression of LTR-driven gene expression by CAF-containing exosomes is abolished in U3A (STAT1-
deficient) cells, whereas it is restored in U3AR (STAT1 rescued) cells. Figure used with permission from 
the Journal of Virology [135] 
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primary CD8+ T cells could suppress HIV-1 replication in infected CD4+ T cells, without 
affecting cell viability (Figure 13). 
 
          
Figure 13: Membranes and exosomes from CD8+ T cells of HIV-1 infected patients also suppress HIV-1 
replication.  
 
 
 
 
 
 
 
 
 
 
Cell membranes and exosome fractions from CD8+ T cells of patient 1 (filled bars) and patient 2 (open bars), 2 
therapy-naïve, HIV-1 infected subjects, can suppress HIV-1 replication in infected primary CD4+ T cells (left 
panel), without affecting cell viability (right panel). Figure used with permission from the Journal of Virology 
[135] 
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4.4 CONCLUSIONS -1 
Our overall aim was to determine the mechanism of action of CAF by which it suppresses HIV 
LTR-driven transcription. Since the identity of CAF is unknown, we used CD8+ T cell- secreted 
exosomes as a source of CAF and to track the interactions of CAF-containing exosomes with 
target cells. Our results so far indicate that exosomes from CD8+T cells can suppress HIV-1 LTR 
driven gene expression by inhibiting mRNA synthesis in CD4+ target cells. We also observed 
that CAF-containing exosomes appear to interact with the TZM-bl target cells at the cell surface, 
as early as 10 minute after addition and did not seem to get internalized. However, maximal 
suppression was observed to occur about 12-16 hours after addition of CAF-containing 
exosomes to the cells. Interestingly, we found that exosomes can be removed within 5 minutes of 
addition to cells and still produce maximal suppression of transcription 12-16 hours later. These 
observations indicate that CAF in the exosomes probably triggers a signal cascade as soon as it 
encounters the cell and this signal cascade ultimately leads to transcriptional suppression of the 
LTR, 12 to 16 hours later. This was corroborated by findings that STAT1 appeared to be 
necessary for the process of suppression by CAF.  
Hence, in the next section, we investigated the role of STAT1 in the transcriptional 
suppression of HIV-1 by CAF.   
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5.0  STAT1-INDEPENDENT SUPPRESSION OF HIV-1 TRANSCRIPTION BY 
PRIMARY CD8+ T CELL-DERIVED ANTIVIRAL FACTOR 
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5.1 ABSTRACT 
CD8+ T cells can inhibit HIV-1 replication in infected CD4+ T cells in a non-cytolytic 
manner by suppressing transcription from the viral promoter. The factor mediating this response, 
referred to as CD8 Antiviral Factor (CAF), and its mechanism of action are unknown. Previous 
reports, using HVS-transformed CD8+ T cell lines, have shown the requirement for the 
transcription factor, STAT1, in CAF-mediated viral transcription suppression. Since STAT1 is 
not known to directly interact with the HIV-1 promoter, we attempted to determine upstream and 
downstream interacting proteins, to uncover novel pathways of viral transcription regulation by 
STAT1. We found Jak1 and Jak2 kinases to be involved in the STAT1 mediated suppressive 
process, in cells treated with CAF from transformed CD8+ T cells (CAFtransformed ). Jak1, Jak2 and 
STAT1 are components of the canonical interferon gamma (IFNγ) signaling pathway. Hence, we 
examined the role of IFNγ in STAT1-mediated suppression of HIV transcription. We found that 
CAF from primary CD8+ T cells from HIV-1 infected subjects (CAFprimary) contained 10-fold 
lower levels of IFNγ than CAFtransformed. Furthermore, IFNγ-depleted CAF primary retained the 
ability to suppress viral transcription in infected primary CD4+ T cells and in STAT1-deficient 
cell lines. In contrast, IFNγ-depleted CAFtransformed could not suppress viral transcription in the 
absence of STAT1. Our results indicate that CAF from primary CD8+ T cells can suppress HIV-
1 replication independent of STAT1 and that CAF transformed may not be a good substitute for 
CAFprimary 
 
 
 
 
 53 
 
5.2 INTRODUCTION 
CD8+ T cells can control HIV-1 replication by non-cytolytic methods [21, 130]. The first 
non-cytolytic antiviral CD8+ T cell response was described in Long Term Non-Progressors of 
HIV-1 infection [21]. The factor mediating this response was termed “CD8 Antiviral Factor” 
(CAF) [137]. Several features characterize the CAF-mediated response. First, there is no 
requirement for MHC restriction or contact between the CD8+ T cell and the target cell [136, 
176]. Second, CAF has been found to be effective against a wide range of HIV-1 clades, as well 
as HIV-2 and SIV and inversely correlates with the stage of disease [151, 153, 154, 156, 157, 
160, 177, 178]. Third, CAF has been noted to suppress transcription from the viral promoter 
[135, 179-182]. Fourth, both R5 and X4 viruses can be equally well suppressed [155, 167]. 
Although many candidate non-cytolytic CD8+ T cell factors have since been described [130-
133], the identity and mechanism of action of CAF are as yet unknown.  
The discovery of CAF was made by using primary CD8 + T cells from human subjects. 
However, the short lifespan of primary T cells in culture, as well as the difficulties in obtaining a 
regular and consistent supply of fresh blood from infected patients prompted the use of Herpes 
virus saimiri (HVS)-transformed CD8 + T cell lines for more detailed studies on CAF and its 
identity. Several of these studies have relied mainly on supernatants from transformed CD8 + T 
cells, as a source of CAF[135, 162-166, 182-184]. A key result uncovered from these studies 
using cell lines knocked out for STAT1 was  that STAT1 was involved in in the process of viral 
transcription suppression in target cells [165].  
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STAT1 is a well characterized signal transducer and regulates the expression of many 
genes involved in innate immunity, cell growth, differentiation and cell death [185, 186]. STAT1 
can function as a signal transducer when it is phosphorylated, although it has recently been 
shown to have multiple signaling roles even in its unphosphorylated state [187]. Kinases known 
to phosphorylate STAT1 are the Janus kinases, Jak1, Jak2, Jak3 and Tyk2. Once phosphorylated, 
STAT1 has multiple interactions with many different proteins, including other STAT proteins, 
interferon regulatory factors (IRFs) [188], and other transcription factors such as SpI [189] , 
NFKB[190], BRCA I[191] and c-myc[192] (Figure 12). The genes induced by STAT1 in each 
case, depending on its interacting partners, may be different.  
 
                     
Figure 14: A schematic drawing showing the common upstream and downstream interacting 
partners of phosphorylated STAT1. 
 
Among the most common inducers of STAT1 is interferon gamma (IFNγ) [193] . IFNγ is 
one of the key cytokines secreted by activated CD8+ T cells and has multiple antiviral effects on 
cells. Recombinant IFNγ has been shown to be able to suppress HIV-1 transcription in HeLa 
based cell lines [194], although its effect on HIV-1 transcription in infected, primary CD4+ T 
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cells is considered to be inconclusive, with reports of inhibition [195-197], enhancement [198] or 
no effect at all on viral transcription [199].  IFNγ interacts with its receptor IFNγR at the cell 
surface, triggering the recruitment of Jak2 to the receptor chain IFNγR2. Jak1, found to be 
constitutively associated with IFNγR1, and Jak2 are activated by trans-phosphorylation at key 
tyrosine residues. Phosphorylated tyrosines present attractive targets for the SH2 domain of 
STAT1, which is, in turn, recruited to and phosphorylated by Jak1 and Jak2 at its Y701 residue. 
Phosphorylated STAT1 dimerizes in response to IFNγ , enters the nucleus, becomes 
phosphorylated at the S727 site and is  activated to function as a potent transcription factor, able 
to induce the expression of interferon-responsive genes [185]. 
Since STAT1 is not known to directly interact with the HIV-1 LTR promoter, we sought 
to determine the immediate upstream and downstream interacting partners of STAT1, in the 
hopes of uncovering novel antiviral pathways coincident with STAT1 activation. However, we 
found that the requirement for STAT1 in the suppressive process was exclusively found only 
when CAF from transformed CD8+ T cell supernatant (henceforth referred to as CAFtransformed) 
was used. In contrast, CAF from primary CD8+ T cells (henceforth referred to as CAFprimary) 
signaled in a STAT1-independent manner to suppress transcription from the HIV-1 promoter. 
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5.3 RESULTS  
1. Role of STAT1 in the process of transcription suppression by CAF from transformed 
CD8+ T cells: 
 
Our previous studies indicated that STAT1 was necessary in the process of HIV-1 transcription 
suppression mediated by CAF from transformed CD8+ T cell lines (CAFtransformed). Although 
STAT1 phosphorylation at the Y701 residue activates its function as a transcription factor [188], 
unphosphorylated STAT1 has also been shown to have important signaling roles [187, 200]. 
Hence, we determined the phosphorylation status of STAT1 in the presence of CAF by Western 
Blot. We found that STAT1 phosphorylation occurred upon CAFtransformed treatment in TZM-bl 
cells (Figure 15) 
 
 
 
 
 
 
 
 
 
 
 
 
Hanks              +CAF 
pSTAT1 
 
B-actin 
 
 
Figure 15: Phosphorylation of STAT1 in TZM-bl cells in response to CAFtransformed  
TZM-bl cells were exposed to either Hanks or to CAFtransformed for 15 minutes before being lysed and probed for 
phosphorylated STAT1 
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Next, we determined the time-and dose-response kinetics of STAT1 phosphorylation by 
quantifying the level of phosphorylated STAT1 using the Luminex assay. We found that there 
was a time and dose dependence to STAT1 phosphorylation by CAFtransformed in TZM-bl cells 
(Figure 16A, 16B. Maximal phosphorylation of STAT1 was seen about 30 minutes after addition 
of CAFtransformed. We also assessed the dynamics of STAT1 phosphorylation by CAFtransformed in 
primary CD4+ T lymphocytes. We treated primary CD4+ T cells either with varying doses of 
CAFtransformed for a fixed period of time or with a fixed dose of CAFtransformed for varying periods 
of time. We found that STAT1 phosphorylation in primary cells was also time- and CAFtransformed 
dose- dependent (Figure 16C, 16D). The percentage of phosphorylation in CD8- cells increased 
from ~0.7% to ~5% when the dose of CAFtranformed was increased from 0.5% vol/vol to 15% 
vol/vol.  
 
2. Role of upstream and downstream interacting partners of STAT1: 
 
Since STAT1 was phosphorylated in response to CAFtransformed, we next sought to 
determine the role of upstream and downstream interacting partners of STAT1 in CAF-mediated 
suppression. Since the most common kinases that phosphorylate STAT1 are the Jak kinases, 
Jak1, Jak2, Jak3 and Tyk2 [201] and STAT2, STAT3, STAT5 and IRF9 are known STAT1 
interacting partners ( Figure 12), we tested the importance of Jak1, Jak2, STAT2, STAT3, 
STAT5 and IRF9 in CAF-mediated transcription suppression by using gene knock-out cell lines 
and by probing the phosphorylation status of these proteins in response to CAFtransformed. The 
knock-out cell lines that we used were U1A (Tyk2 knock out), U2A (IRF9 knock out), U4A  
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C                         D                
 
 
Figure 16: Time- and dose- dependence of phosphorylation of STAT1 in response to CAFtransformed 
 
 
 
The time and dose dependence of phosphorylation of STAT1 in TZM-bl cells ( A and B) upon exposure to 
CAFtransformed and in primary CD4+T cells (C and D) were determined by Luminex bead assay. The y-axis is the 
percentage of phosphorylated STAT1 (pSTAT1) in the cells.  
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(Jak1 knock out), U6A (STAT2 knock out) and G2A (Jak2 knock out), previously described 
[202-204]. In experiments involving these knock-out cell lines, we pre-treated each of the cell 
types with CAFtransformed, and then transiently transfected the cells with a LTR-luciferase reporter 
plasmid. After PMA stimulation, we measured luciferase expression from LTR in the CAF-
treated cells, and compared it to the control-media treated cells.  We found that the cells knocked 
out for Jak1 and Jak2 proteins only  suppress LTR driven reporter gene expression to ~7-8%, 
indicating that these proteins were necessary for suppression. However, ~95% suppression of 
luciferase expression from the LTR-luc plasmid upon CAFtransformed treatment still occurred in the 
cell lines U1A, U2A and U6A, deficient in Tyk2, IRF9 and STAT2 respectively, indicating that 
these proteins were not involved in the suppression process (Figure 17). 
 
 
Figure 17: Suppression of LTR-gene expression by CAFtransformed in cells deficient for different proteins 
 
 
Cells deficient in each of the signaling proteins above were treated with either CAFtransformed or 
Hanks control and then transfected with LTR-luc plasmid. Luciferase production from the LTR 
was measured after PMA stimulation of the cells. The degree of suppression of LTR gene 
expression in CAF treated cells was calculated relative to the control cells 
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Western blots of TZM-bl cell lysates showed that STAT3 and STAT5 were not 
phosphorylated after treatment of these cells with CAF, whereas in control TZM-bl cells treated 
with IL2, phosphorylated STAT3 and STAT5 was readily detected (Figure 18). Since Jak3 
phosphorylation also results in the concomitant phosphorylation of STAT3 [201] and STAT3 
phosphorylation was not detected upon CAF treatment, we concluded that Jak3 was not involved 
in CAF-mediated transcription suppression.   Thus, the main signaling partners of STAT1 found 
to be involved in the suppression of gene expression from the HIV-1 LTR, were Jak1 and Jak2. 
 
 
 
 
 
 
 
 
3. Role of IFNγ in the CAF-mediated signaling process: 
Thus far, we have determined, using CAFtransformed, that the signaling proteins necessary 
for the suppressive action by CAF were Jak1, Jak2 and STAT1. These signaling proteins are also 
important constituents of the canonical interferon gamma (IFNγ) signaling pathway. High IFNγ 
levels in CAFtransformed would explain the requirement for Jak1, Jak2 and STAT1 in the signaling 
process.  
Figure 18: STAT3 and STAT5 are not phosphorylated in response to CAFtransformed.  
The phosphorylation states of STAT3 and STAT5 were studied by Western blots in TZM-bl 
cells treated with CAFtransformed or a positive control (IL2) for 15 minutes 
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Therefore, we next measured the level of IFNγ in supernatants from the transformed 
CD8+T cells as well as from primary CD8+T cells from HIV-1 infected individuals. We found 
that samples from transformed CD8+T cells indeed had consistently higher levels of IFNγ 
(>4000pg/mL) than supernatants derived from most of primary CD8+T cells (<200pg/mL) (Table 
5-1).  
 
Table 5-1: IFNγ levels in CD8 culture supernatants. 
 
Source of CAF IFNγ levels 
(pg/mL) 
Patient 1 12 
Patient 2 16 
Patient 3 74 
Patient 4 61 
Patient 5 186 
Patient 6 794 
TG 1 3050 
TG 2 7290 
TG 3 8050 
TG 4 10880 
 
 
 Next, we sought to determine if IFNγ depletion from the CD8+T cell culture supernatants would 
affect the ability of CAFtransformed to suppress LTR- gene expression. IFNγ was depleted from 
culture supernatants by serial incubation on IFNγ antibody- coated plates. The percentage of 
depletion by this method was nearly always greater than 90% (see Table 5-2 for IFNγ levels 
IFNγ in CAFprimary from 6 different HIV-1 infected patients and in CAFtransformed from 4 different batches of the 
transformed cell line TG was measured by ELISA 
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before and after depletion in transformed CD8 and primary CD8 culture supernatant samples).  
 
Table 5-2: IFNγ levels in culture supernatants of CD8+ T cells before and after depletion 
 
        
 
 
 
 
IFNγ was measured in the supernatants of transformed CD8+ T cells, TG, from 4 different 
batches and primary CD8+ T cells from 7 different patients 
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Following IFNγ depletion, we compared the ability of the depleted samples to suppress LTR 
mediated reporter gene expression with those which had undergone a control-depletion with 
nonspecific IgG antibody. We found that IFNγ-depleted CAFtransformed could no longer suppress 
LTR-transcription in TZM-bl cells, as compared to the non-depleted CAF samples (Figure 19). 
                       
 
 
Figure 19: Depletion of IFNγ abolishes suppressive ability of CAFtransformed in TZM-bl cells.  
 
 
To determine if suppression of HIV-1 replication in primary, infected CD4+ T cells by 
CAFtransformed CD8 was affected by IFNγ depletion, we cultured the infected CD4+ target cells in 
the presence of either IFNγ-depleted CAFtransformed or non-depleted, control CAFtransformed. In 
contrast to the results seen with TZM-bl cells, we found that IFNγ depleted CAFtransformed could 
suppress p24 production to nearly the same extent as the non-depleted samples in acutely 
infected primary CD4+ T cells (Figure 20). 
1                        2                  3                     4                        5 
Batches of CAFtransformed 
5 different batches of CAFtransformed were IFNγ-depleted and their ability to suppress LTR 
transcription was compared to non-depleted controls in TZM-bl cells 
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Figure 20: Depletion of IFNγ does not affect ability of CAFtransformed to suppress HIV-1 replication in primary 
CD4+ T cells.  
 
 
Next, we sought to determine the effect of IFNγ depletion on the suppressive ability of 
CAFprimary. IFNγ-depleted CAFprimary showed no change in the ability to suppress HIV-1 p24 
production, compared to the non-depleted controls, in acutely infected primary CD4+ T cells, in 
8 out of 9 cases (Figure 21). The suppression of p24 production by IFNγ depleted CAFprimary was 
also dose dependent (Figure 22). 
 
 
 
 
 
 
IFNγ -depleted (“IFNg-depl”) and non-depleted (“control”) CAFtransformed CD8 were assayed for their ability to 
suppress HIV-1 transcription acutely infected primary CD4+ T cells 
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Figure 21: Depletion of IFNγ from CAFprimary does not affect its ability to suppress HIV-1 replication in 
primary CD4+ T cells.  
  
 
 
Figure 22: Dose dependence of suppression of HIV-1 replication by CAFprimary.  
 
 
 
 
 
 
Non-depleted (“control”) and IFNγ-depleted (“ID”) samples from 9 different HIV-1 infected patients were assayed 
for their ability to suppress HIV-1 replication in primary CD4+T cells, by measuring p24 levels 
Dilutions of non-depleted (“control”) or IFNγ-depleted (“ID”) supernatants from one of the patient CD8+ T cells 
were used to examine the dose dependence of the suppression of HIV-1 replication in infected CD4+ T  cells. 
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These results indicate firstly that, transformed CD8+T cell supernatants do contain 
significantly higher levels of IFNγ than primary CD8+T cell supernatants. These results also 
indicate IFNγ depletion does not affect the ability of either CAFtransformed CD8 or CAFprimary CD8 to 
suppress HIV-1 replication in infected CD4+ T cells. We also found that TZM-bl cells may not 
be sensitive to factors other than IFNγ that mediate LTR suppression, thus implying that the 
choice of assay for measuring suppressive ability of CAF is important.  
 
4. Role of STAT1 in suppression by IFNγ-depleted CAF from primary CD8+ T cells: 
Our results so far have shown that culture supernatants of transformed CD8+ T cell contain 
significantly higher levels of IFNγ than that of primary CD8+T cells. Since CAFtransformed signals 
via Jak1, Jak2 and STAT1, which are constituents of the IFNγ signaling pathway, we 
investigated whether STAT1-mediated viral suppression was due to IFNγ present in this source 
of CAF. 
To address this, we once again used the STAT1-deficient and rescued cell lines, U3A and 
U3AR, which had been used previously to establish the importance of STAT1 in viral 
transcription suppression.  U3A and U3AR cells were treated with non-depleted or IFNγ-
depleted CAFprimary and CAFtransformed, following which, the cells were transiently transfected 
with LTR-luc plasmid. After PMA stimulation, luciferase expression from the LTR was 
measured. Although suppression by CAFtransformed still required STAT1 (Figure 23), we observed 
no difference between the suppression of gene expression from the LTR in U3A and U3AR cells 
in all samples of IFNγ-depleted CAFprimary, indicating that STAT1 had no role to play in the 
process of viral transcription suppression when CAFprimary was used (Figure 24).  
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Figure 23: Requirement for STAT1 for suppression by non-depleted and IFNγ-depleted CAFtransformed  
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Figure 24: STAT1 independent suppression by non-depleted or IFNγ-depleted CAFprimary  
 
 
 
STAT1 deficient (U3A) and rescued (U3AR) cell lines were used to analyze the role of STAT1 in suppression of LTR 
driven transcription mediated by 3 batches (TG1-TG3) of non-depleted (“contrl”) or IFNγ-depleted (“IFNg depl”) 
CAFtransformed 
STAT1 deficient (U3A) and rescued (U3AR) cell lines were used to analyze the role of STAT1 in CAF-mediated 
suppression of LTR driven transcription. Both cell types were exposed to non depleted (“control depl”) or IFNγ-
depleted (“IFNg depl”) CAFprimary from 3 different HIV-1 infected patients (Pt1- Pt 3) and then transfected with 
LTR-l 
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MTT assays indicated no loss in cell viability after incubation with supernatant samples 
(data not shown). Overall, our results indicate STAT1-independent suppression by CAFprimary. 
 
5. Role of PI3K, MAPK and other common signaling proteins in CAFprimary-mediated 
suppression: 
Previous investigations have shown that significant levels of suppression of viral transcription 
are only seen about 12-16 hours after addition of CAF to CD4+ cells (Figure 7 and [135]). Our 
data also indicates that CAF might trigger a intracellular signal soon after addition to cells, which 
ultimately leads to viral transcription suppression 12-16 hours later. This indicates the necessity 
for expression of intermediate proteins which might directly suppress transcription from the 
LTR. Since STAT1 was not involved in the process of suppression by CAFprimary, we 
investigated whether any other protein could be considered a suitable marker for CAF activity. 
This included proteins like the kinases p38 MAPK, JNK or PI3K which are components and key 
regulators of multiple signaling pathways in the cell. It might be possible that CAF signaling 
could result in the phosphorylation of some of these proteins. Hence, we examined the 
phosphorylation status of 10 different proteins in acutely HIV-1 infected, primary CD4+ T cells 
that had been treated for various intervals of time with CAFprimary. These proteins were p38 
Mitogen Activated Protein Kinase (p38 MAPK), Phosphotidyl inositol 3 kinase (PI3K), 
Phospholipase C γ2 (PLCγ2), Jun N terminal kinase (JNK), Janus kinase 3 (Jak3), Signal 
Transducer and Activator of Transcription 3 (STAT3), Interleukin 15 receptor alpha chain 
(IL15Ra), Fibroblast Growth Factor Substrate (FRS2) and the adaptor proteins Crk, and Tec 
kinase. Some of these proteins are known to modulate HIV-1 transcription. For example, PI3K 
and IL15 are known to inhibit HIV-1 transcription and enhance CAF activity, respectively [205, 
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206]. JNK, p38 MAPK and FRS2 are known to activate HIV-1 transcription [207, 208]. Other 
proteins, like STAT3, are known to be intermediates in pathways that generate HIV-1 
transcription inhibitors [209]. PLC-γ2 and Tec kinase are involved in regulating the levels of 
intracellular calcium, which has modulating effects on HIV-1 transcription [210-212]. The 
adaptor protein, Crk, is an intermediate in many MAPK pathways and connects multiple stimuli 
to the JNK pathway [213].  
Since this entire set of proteins is activated by phosphorylation, we determined the 
phosphorylation status of these proteins at various time after CAF treatment. For this purpose, 
acutely HIV-1 infected, primary CD4+ T cells were exposed to IFNγ depleted or control CAF 
from primary CD8+T cells of 3 HIV-1 infected subjects for 10 minutes, 20 minutes, 12 hours or 
42 hours and probed for tyrosine phosphorylation. Concomitantly, we also measured the 
suppression of p24 production in acutely infected CD4+ T cells by the same CAF samples and 
confirmed that the degree of suppression was about 60-70% in all cases. We saw no consistent 
significant difference in phosphorylation of any of the 10 proteins studied at any of the time 
points, compared to PBS-only controls (Figures 25A-D). Thus, we were unable to find a 
molecular marker for the suppressive activity of CAFprimary with the methodology used.  
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Figure 25: Role of PI3K, p38MAPK and other common signaling proteins in suppression mediated by CAFprimary. 
   C             D 
Exogenously infected primary CD4+T cells were exposed to either non-depleted or IFNγ-depleted CAFprimary (referred to 
as “control” or “ID” in figure) from 3 different HIV-1 infected patients or media control for 15m, 25m or 12h and then 
lysed and processed for measuring phosphorylation, using Epiquant technology (Millipore, Billerica, MA). The 
phosphorylation of 10 different proteins was measured against a standard cocktail of phosphorylated peptides provided by 
the manufacturer at 10 min (A), 25 min (B), 12 hours (C) or 42 hours (D) of CAF treatment. 
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5.4 CONCLUSIONS – 2 
Our results from Specific Aim 1 indicated the involvement of an intracellular signaling cascade 
triggered by CAF, which might ultimately lead to viral transcriptional suppression. Previous 
work, by us and by others, had indicated the importance of STAT1 in this process. Hence, we 
examined the role of STAT1 in the process of CAF-mediated viral transcription suppression.  
 
We found that Jak1 and Jak2 were the upstream interacting partners of STAT1 in the 
CAF-mediated suppressive process. Since Jak1, Jak2, and STAT1 are components of the IFNγ 
signaling pathway, we examined the role of IFNγ in suppression. Our results indicate that 
transformed CD8+ T cell culture supernatants contain IFNγ at levels about 10 times higher than 
that from primary CD8 cells. The high levels of IFNγ lead to misleading results about the role of 
Jak1, Jak2, and STAT1 in the process of transcription suppression by CAFtransformed. However, 
even in the absence of IFNγ, CAFtransformed shows a requirement for STAT1, that is not indicated 
by CAFprimary, indicating that differing IFNγ levels may not be the only reason for the opposite 
results with CAFtransformed and CAFprimary. Figure 26 summarizes the main differences between the 
two sources of CAF. Since CAFtransformed and CAFprimary also exhibited different suppressive 
abilities in TZM-bl cells and primary CD4+ T cells, we summarized the major differences. Table 
5-3 summarizes the ability of various sources of CAF to suppress in the two different assay 
sytems, the TZM-bl transcription and CD4+ T cell HIV-1 acute infection assays. 
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Table 5-3: Summary of suppressive ability of CAF sources in different assays 
Assay/CAF source TZM-bl transcription assay 
 
(% suppression) 
CD4+ T cell acute infection 
assay 
(% suppression) 
CAFtransformed >90% [135] >90%  [135] 
IFNγ-depleted 
CAFtransformed 
~ 0 (Figure 19)  ~90% (Figure 20)  
CAFprimary Not performed Variable (Figure 21, 22) 
IFNγ-depleted CAFprimary Not performed Same as non-depleted (Figure 
21,22) 
 
 
 
 
 
CAF source 
CAFtransformed 
• ng/mL IFNγ 
• STAT1 dependent suppression 
 
CAFprimary • pg/mL IFNγ 
• STAT1 independent suppression 
 Figure 26: Summary of differences between CAFtransformed and CAFprimary 
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Since phosphorylation is one of the most common ways by which signals are transduced within 
cells, we then sought to determine other signaling molecules that might be phosphorylated in 
response to CAFprimary. We determined the phosphorylation of 10 different proteins, which were 
known to either directly regulate HIV-1 transcription or were components of pathways that 
converged on the LTR. However, none of these proteins were seen to be consistently 
phosphorylated in response to CAFprimary. Our results indicate the requirement for a STAT-1 
independent signaling pathway in the process of HIV-1 transcriptional suppression by CAF from 
primary CD8+ T cells. 
 
We next turned our attention to the HIV-1 promoter, the Long Terminal Repeat (LTR), in the 
hopes of uncovering a region that was necessary for the suppressive process, and which might 
provide additional clues as to the signaling molecules involved. 
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6.0  IDENTIFICATION OF THE REGION ON THE HIV-1 LONG TERMINAL 
REPEAT RESPONSIBLE FOR TRANSCRIPTIONAL SUPPRESSION BY THE CD8 
ANTIVIRAL FACTOR 
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6.1 ABSTRACT 
The CD8 Antiviral Factor (CAF) is known to suppress transcription from the HIV Long 
Terminal Repeat (LTR) promoter, in a non-cytolytic manner. However, the region on the LTR 
that is crucial for the suppressive activity of CAF is unknown.  Serial deletions of the HIV-1 
LTR indicated a short ~90 bp segment containing the 3 SpI sites and TATA box on the LTR is 
sufficient for CAF-mediated transcriptional suppression. Furthermore, we found that the 3SpI-
TATA segment, with no other upstream modulators or enhancers, could independently support 
transcription and suppression. Thus, the changes in protein binding occurring on the HIV-1 
minimal promoter, spanning the 3 SpI sites and TATA box of the LTR, likely lead to 
transcriptional suppression by CAF. 
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6.2 INTRODUCTION 
The aim of this part of the project is to identify the region on the HIV-1 promoter, the 
Long Terminal Repeat, which was crucial for the process of transcriptional suppression by CAF. 
The studies described in earlier sections of this thesis imply that CAF may mediate its 
suppressive effects through the production of an intermediate protein which might lead in 
alteration of transcription factors binding to the viral promoter, the HIV-1 Long Terminal Repeat 
(LTR), leading to decreased transcription. The HIV-1 LTR consists of 3 regions: U3, R and U5. 
The core promoter of HIV consists of 3 non-identical GC-rich SpI binding sites (-78 to -46) 
along with the TATA box (-28 to -20), on the U3 region [214, 215].  Immediately upstream of 
the SpI binding sites are 2 sites for the transcription factor NFKB (-105   to -79), an important 
enhancer and modulator of HIV transcription [216]. Other upstream enhancer elements include 
NFAT, ApI, COUP-TF, Ets and USF [217-219]. Downstream of the TATA box (+3 to +59) is 
the HIV Tat protein binding region, known as the Transactivating Region (TAR) [215, 
220](Figure 27). Transcription begins with the binding of cellular transcription factors NFKB, 
SpI, TATA binding protein (TBP) and RNA Pol II to the cognate sites, upon which nascent 
mRNA is produced. A characteristic hairpin loop with bulge structure is formed by the nascent 
mRNA, which is known as the TAR loop. The viral protein Tat binds to TAR, recruiting the 
transcription elongation factor pTefb [221, 222]. The cdk9 component of pTefb is a cyclin 
dependent kinase. It phosphorylates the C terminus of RNA Pol II, increasing its processivity and 
resulting in the elongation of the viral mRNA [222].  Since most of the transcription regulatory 
sites are located in the U3 and R regions, we concentrated on these regions to determine the 
target site for transcriptional suppression by CAF.  
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A recent paper by Bonneau et al [223]examined the effect of deletions and inactivating 
point mutations in individual transcription binding factor sites on the LTR on CAF activity. 
Specifically, the authors performed mutational analyses to investigate the role of the 
transcription factors NFAT (-256 to -234) and ApI (at -351 to -327 and -310 to -289), the 
Interferon Stimulatory Response Element (ISRE, which is a binding site, situated at +198 to 
+219, for interferon regulatory factors, IRFs), and IL2-homology Purine Rich Response Element 
(PRRE, at -274 to -256). They also studied the role of the 2 NFKB sites and the 3 SpI sites by 
deleting them separately and disrupted the TAR-Tat axis by mutational inactivation of the Tat 
gene and TAR. Their results showed that full length HIV-1 molecular clones bearing these 
individual mutations and deletions could still exhibit suppression of replication in the presence of 
CAF.  Hence, we considered the possibility that more than one transcription factor binding site 
on the LTR might be involved in the process of the CAF-mediated HIV transcriptional 
suppression. Therefore, instead of introducing point mutations as described by Bonneau et al, we 
serially deleted LTR constructs, to identify the minimal region responsible for CAF-mediated 
transcriptional suppression. Our data suggest that a 90bp region containing the 3 SpI sites and the 
HIV TATA box is sufficient for transcriptional suppression by CAF.  
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-119 
-83 
-69 
Figure 27: Schematic of the HIV-1 LTR and LTR deletion constructs.  
Upper panel shows cartoon of the entire 650bp HIV-1 LTR and is used with permission from Expert 
Reviews in Molecular Medicine 
 79 
6.3 RESULTS 
To explore the possibility that more than one TF binding site may be acting together to 
suppress LTR driven transcription, we focused on the U3 and R regions in our study. The main 
segments of the U3 region were the Negative Regulatory Element (NRE) (-340 to -184), the 2 
NFKB sites, the 3SpI sites, and the TATA box (Figure 27).   
 
1. Measurement of transcriptional suppression  in serially deleted constructs of the LTR: To 
study if there are multiple TF binding site acting in conjunction with each other to initiate 
CAF-mediated suppression of transcription from the LTR in the presence of CAF, we 
used LTR constructs which had been serially deleted of key TF binding sites.  These 
constructs were the full length Wt-LTR, the EcoRV construct (containing deletion of the 
NRE), the BstNI construct (containing deletions up to the SpI sites), and the Hae III 
construct (deletion up to the SpI (II) site) as shown in Figure 24. Each of these constructs 
was transfected into 293T cells, pretreated with either CAF or media control, and then 
stimulated with PMA. LTR driven reporter gene expression was then measured. We 
found that CAF was able to suppress reporter gene expression from all of these constructs 
(Figure 28) 
These results indicate that the region encompassing the -69 to +83 of the LTR is 
sufficient for the transcription suppressive action of CAF.  
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Figure 28: Suppression of transcription by CAF from various LTR deletion constructs 
 
 
2. Role of the TAR loop in conferring susceptibility to CAF: The results above indicate that 
the smallest segment of the LTR that was able to do was the HaeIII segment, containing 
the 1st 2 SpI sites, the TATA box and TAR region. However, we decide focused our 
attention on all three of the SpI sites, because the SpI sites of the LTR have been shown 
to be crucial for modulating transcription and SpI (III) is especially important because it 
can recruit activating and repressing transcription factors [224-226]. Hence, we focused 
our attention on the BstNI construct which contains the 3 SpI sites, HIV TATA box and 
TAR regions.   
The TAR region is a very attractive candidate target for CAF action. It has a 
unique bulge-loop structure and is well-conserved across all clades of HIV-1 [227].  If 
TAR were the target for CAF, it would help explain the specificity of CAF for HIV. 
Previous investigations on the region of the LTR necessary for CAF action, created 
CAT protein production from various LTR deletion constructs in the presence and absence of CAF. Wt refers 
to the full length (-454 to + 83) LTR upstream of the CAT reporter gene.  The positions of the LTR truncations 
by each of the restriction enzymes, EcoRV, BstNI, and HaeIII are as shown in Figure 27. 
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inactivating, point mutations of the TAR to disrupt the Tat-TAR axis [223]. But if the 
structure of TAR were somehow important for CAF action, point mutation alone might 
not indicate the importance of TAR in suppression. Critical interactions between the 
TAR, Tat and pTefb take place on the bulge-loop structure on TAR [228, 229] Hence, we 
deleted the bulge-loop region of TAR (shaded in Figure 29A, right panel) from the BstNI 
segment, to form a new construct called BstΔTAR, to evaluate any changes in 
susceptibility to CAF.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Deletion of the TAR region in the LTR construct.  
                                                 SpI   TATA  
Reporter gene 
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Schematic of TAR deletion (left panel). The secondary structure of wt TAR (right panel). The 
arrows point to the two sites in the TAR where the deletion was made. The shaded region shows the 
region that was deleted 
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Contrary to expectations, the TAR deleted construct was still transcriptionally active and was 
suppressed by CAF transcription from the LTR (Figure 30). We reasoned that the absence of 
any upstream LTR elements in the BstΔTAR construct may be a reason why TAR deletion 
still supported transcriptional ability of the construct. We concluded that the TAR element is 
not the target region for transcriptional suppression by CAF. 
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Figure 30: Suppression of reporter gene expression from the BstΔTAR construct in the presence of CAF 
 
 
 
3. Role of the SpI sites in CAF-mediated suppression:  We next sought to determine if any 
of the SpI sites might be important in the suppressive process. For this purpose, we first 
deleted each SpI site individually or in pairs, in the presence of the deleted TAR, to check 
for changes in response to CAF. The schematic in Figure 28 details the deletions made. 
BstdelTAR construct was transfected into 293T cells that had been pre-treated with CAF. CAT reporter 
production was measured after stimulation of the LTR with CAF. 
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As shown in Figure 31, deletion of the SpI sites had different effects on LTR driven 
transcription. Deletion of SpI (III) alone, in the absence of TAR, made the construct 
transcriptionally inactive, highlighting the importance of this site as well as TAR in HIV-
1 transcription, as has been reported earlier [230]. Deletion of SpI(I) or SpI (II) alone did 
not affect the ability of the construct to transcribe upon activation LTR-driven gene 
expression or get suppressed when exposed to CAF. However, deletions of both SpI (I) 
and SpI (II) made the construct transcriptionally inactive.  
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Figure 31: Suppression by CAF of transcription from SpI-deletion constructs of the HIV-1 LTR.  
 
 
To confirm that the observed results were a product of SpI site inactivation and not 
because the of the deletion process itself, we next inactivated the SpI sites by point 
Deletions of the SpI sites, individually or pairwise, on the 3SpI-TATA segment of the HIV-1 LTR were 
made. Deletions affected transcription from this segment, although suppression by CAF was seen as long as 
transcription was supported 
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mutation. Inactivation of the SpI sites, either individually or in pairs, was done by 
replacing key G residues in the SpI binding sites with T.  Mutation of the SpI sites did not 
transcriptionally inactivate the construct, in accordance with previous reports [231].  
However, mutation of the SpI (III) site did reduce the ability of the construct to drive 
transcription, to ~500 RLU compared to the ~1500 RLU of luciferase production by the 
single mutations in the remaining SpI sites. While inactivation of SpI (I) or SpI (II) alone 
did not appear to significantly reduce transcription, mutation of both SpI (I) and SpI (II) 
simultaneously reduced transcription by nearly 50%. Mutation of SpI (I) or SpI (II) with 
SpI (III) reduced the transcription ability even further (Figure 32). All constructs were 
able to support transcription, albeit to different degrees, compared to the deletion mutants 
(Figure 30). However, the results with the SpI point mutations broadly corroborate with 
those obtained using the SpI deletion mutants   
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Figure 32: Suppression by CAF of transcription from SpI-point mutation constructs of the HIV-1 
LTR.  
 Inactivating point mutations of the SpI sites, individually or pairwise, on the 3SpI-TATA segment of the 
HIV-1 LTR were made. Inactivation by mutation affected transcription from this segment, although 
suppression by CAF was seen as long as transcription was supported 
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While these constructs gave further insight into the role of the SpI sites in HIV 
transcription, we still could not parse out which sites were crucial for CAF suppressive 
activity. This was especially so, because the processes of transcription and suppression of 
transcription were inextricably linked. The generation of an “ideal” transcriptionally 
active construct, resistant to CAF action, could not be achieved by inactivating the SpI 
sites alone or in pairs.  
 
All the data described above indicate that the 3SpI-TATA box is the smallest segment of 
the HIV LTR that can independently transcribe and get suppressed by CAF. We noticed 
that the Wt, EcoRV, BstNI and HaeIII LTR constructs carrying the 3SpI-TATA box and 
TAR (used in Figure 27 and described in [168, 232]) contained upstream GAL4 and 
adenovirus E1B sequences. We first sought to investigate if removal of these upstream 
GAL4 sequences would have any effect on the ability of the constructs to suppress HIV 
transcription when exposed to CAF. Secondly, we wanted to determine if the 3SpI-TATA 
segment of HIV LTR could independently transcribe and get suppressed in response to 
CAF, in the absence of any other enhancer or promoter elements and TAR sequence. 
Hence, we inserted the HIV minimal promoter construct upstream of the luciferase 
reporter gene in a promoter-less vector, pGL4.10 and determined if it was transcription 
competent. We found that that the 3SpI-TATA segment could be inserted into a 
promoterless reporter gene construct and it could still undergo LTR-driven transcription. 
Addition of CAF from 2 different batches of transformed CD8+ T cell culture 
supernatants as well as CAF from primary CD8+ T cells from an HIV infected individual 
suppressed transcription from this construct efficiently (Figure 33).  Since results from 
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Specific Aim 2 have indicated that interferon gamma (IFNγ) may also play a role in 
suppressing transcription from the HIV LTR, we determined if IFNγ-depleted 
supernatant from CAFtransformed and CAFprimary samples could also suppress LTR driven 
transcription. Our results show that IFNγ depleted CAF could also suppress transcription 
from the 3SpI-TATA construct, and indicate, once again, that there is indeed a non-IFNγ 
component in CD8+ T cell culture supernatants that can suppress LTR transcription 
(Figure 33). Further deletions of the SpI inactivated the construct (data not shown), 
corroborating our previous results with the SpI deletion constructs, shown in Figure 31 
.  
 
                
Figure 33: Suppression of transcription from the 3SpI-TATAA LTR segment by different CAF 
treatments 
 
 
The 3SpI-TATA segment is able to transcribe independently and suppress transcription in the 
presence of 3 different sources of CAF, either used “as is” or IFNγ depleted: CAF1 and CAF2 
are from 2 different batches of supernatant from transformed CD8, CAF primary is from primary 
CD8 cells from an HIV-1 infected patient.  
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6.4 CONCLUSIONS- 3 
We sought to determine the region on the HIV-1 LTR that was crucial for the process of viral 
transcriptional suppression by CAF. Serial deletions and point mutation analyses of the LTR 
indicated that this region was ~90 bp in length and contained 3 SpI sites and the TATA box. The 
3 SpI sites and TATA box of the LTR constitute the minimal promoter of HIV-1. Our results 
also indicate that each individual SpI site contributes differently to the process of transcription, 
depending upon the presence or absence of the TAR loop. In the presence of TAR, the third SpI 
site, SpI (3) can be deleted without any effect on the ability of the construct to support 
transcription. In the absence of TAR, however, the deletion of SpI (3) abolishes the ability of the 
construct to support transcription. Thus, the only region that could independently support 
transcription as well as respond to the suppressive effects of CAF was the 3SpI-TATA of the 
HIV-1 LTR.   
  
 
 
 
 
 
 
 88 
7.0  OVERALL DISCUSSION 
CAF is a non-cytolytic CD8 cell secreted factor that can suppress HIV transcription. The 
identity and mechanism of action of CAF are unknown. The overall aim of this project was to 
determine the mechanism of action of CAF. Towards this goal, we formed three specific aims: a) 
to examine the interaction between CAF and its target cells, b) to identify the signal cascades 
triggered by CAF which would lead to transcriptional suppression from the HIV-1 promoter, the 
LTR and c) to identify the region of the HIV-1 LTR necessary for CAF action.  
 
HIV-1 suppression was observed by CAF present both in a soluble form in the culture 
supernatant as well as in a membrane-bound form on the surface of intact CD8 T cells. Since the 
identity of CAF is unknown, it was not possible to directly observe its interaction with its target 
cells. However, previous work from our lab showed that CAF was present on small membrane 
vesicles, known as exosomes, which were secreted by CD8+ T cells. Hence, we used these 
exosomes as markers for CAF and evaluated their interactions with target CD4+ cells. Since CAF 
was associated with the exosomes, it was likely that we could extrapolate the interactions of CAF 
with the target cells from those of the exosomes with the cells. 
 
We observed that CAF-containing exosomes interacted with target cells at the cell 
surface and that this interaction took place as early as 10 minutes after addition of exosomes to 
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cells.  Our studies using labeled CAF-containing exosomes showed, by confocal microscopy, 
that exosomes were not internalized into the cells and their interactions, even after 12 hours of 
exposure to cells, are restricted to the cell surface. Our studies with the kinetics of CAF activity 
indicated that cells required a time interval of 12-16 hours between CAF addition and 
suppression of gene expression.  These results suggested the involvement of some intracellular 
signaling cascade in the process of suppression and indicated a role for the signal transducer and 
transcription factor, STAT1 (as shown in Figure 12).  
 
A few caveats are present in this study using the CD8 T cell-derived exosomes to study 
CAF interactions. Since we did not study the interaction of “control” exosomes which lack CAF, 
it is possible that the surface-restricted interactions observed between the CAF-exosomes and 
target CD4+ cells are solely because of the property of the exosomes and not specific to CAF. 
Furthermore, as the size of exosomes is as little as 100nm, it is likely that the exosomes in our 
confocal microscopy data represented by the red dots actually are clumps of exosomes, instead 
of individual vesicles. The process of fluorescently labeling exosomes with Cy5 dye might cause 
them to clump or adversely affect their shape in other ways. Whether the process of labeling the 
exosomes impacts the interaction of exosomes with target cells is unknown. However, given the 
current lacunae in our knowledge of CAF and its identity, we have no other means to examine 
the interactions of CAF. 
 
The second specific aim of this project investigated the role of STAT1 in the process of 
transcription suppression. Since its identity is unknown, the study of CAF has mainly relied on 
unpurified sources of CAF. While we used CD8 exosomes as a CAF source and as a tool to track 
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its interactions in specific aim 1, isolating exosomes is a labor-intensive process. Previous results 
from our lab had also shown that different CAF sources, such as CD8 exosomes or CD8 culture 
supernatant, suppressed HIV-1 transcription in very similar ways.  Hence, we used culture 
supernatants from transformed CD8+ T cells for the remainder of this project.  
 
Culture supernatants from transformed CD8+ T cells have been used in studies on CAF 
for about 2 decades [162, 164]. They have provided an ideal alternative to the problems faced 
with using primary CD8+ T cells, namely, short life span and difficulty in obtaining large 
quantities of blood samples from HIV-1 infected patients. Previous studies, using supernatants 
from transformed CD8+ T cells, have shown that the signal transduction protein, STAT1, is 
necessary for the process of viral transcription suppression. However, the process of 
transformation has been known to lead to pleiotropic changes in the cell. The secretion of 
cytokines, such as IL4, IL17 and IL26, has been shown to be altered by the transformation 
process [233-235]. In fact, IL17 and IL26 were discovered in HVS-transformed CD8+ T cells. 
Changes have also been noted in the activation of protein kinases, such as Lck, a protein crucial 
in T cell development and activation, as also in the expression of certain miRNAs, after 
transformation [236, 237]. While there has been no study to examine the secretion of interferon 
gamma (IFNγ) from these cells, it is not surprising that transformed cells produce more of this 
cytokine. The process of transformation of CD8+ T cells by HVS can activate them. The HVS 
protein, Tip 484, has been shown to activate p56 lck [233, 237], a kinase known to interact with 
and activate STAT1 and STAT3 proteins [237]. STAT1 and STAT3 have been found to be 
crucial for the activation of the transcription factors T-bet and Bcl3, both of which induce the 
production of IFNγ [238, 239]. Thus, it is not surprising that we found higher concentrations of 
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IFNγ in supernatants from the transformed, as compared to primary CD8+ T cells from HIV-1 
infected patients.  
 
IFNγ, by itself, has been known to suppress HIV-1 transcription both in HeLa-derived 
cell lines and in acutely infected CD4+ T cells [195-197]. One way by which this could occur is 
through the action of c-myc. IFNγ can regulate the expression of c-myc through STAT1 
phosphorylation [192]. C-myc and SpI are known to cooperatively bind HDAC1 to repress HIV-
1 transcription [240]. Thus IFNγ, present in cell culture medium, could very well contribute to 
the process of HIV-1 transcription suppression. However, using IFNγ depleted CAF, we have 
shown that both CAFtransformed and CAFprimary still retained their ability to suppress HIV-1 
transcription/replication (Figure 12C and 12 D). Therefore, IFNγ is not the sole contributor of the 
antiviral activity present in CD8+ T cells.  In our experiments using STAT1 deficient cell lines 
and IFNγ-depleted CAF, we observed that HIV-1 suppression by CAFprimary did not require 
STAT1 (Fig 13B), but CAFtransformed still required STAT1 to suppress HIV-1 even after IFNγ 
depletion. This observation corroborated our earlier finding that there was little correlation 
between pSTAT1 levels and the degree of HIV-1 suppression in cells treated with CAFprimary 
(Fig17 A and B). 
 
Our results contradict those reported by Chang et al. In their article, Chang et al. showed 
evidence for the necessity of STAT1 for the process of HIV-1 transcription suppression, using 
CAFtransformed [165]. They also found the IFNγ-inducible protein, IRF1, to be activated in 
response to CAF. The investigators had considered the possibility of a confounding role played 
by IFNγ. Finding a wide range of IFNγ concentrations in the three HVS-transformed CD8+ T cell 
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lines that they tested, they immune-depleted IFNγ from their CAF preparations by using 
neutralizing antibody to the cytokine and concluded that IFNγ is not a confounder in interpreting 
the results on CAF. We have found that a single incubation with neutralizing antibodies was 
ineffective in removing all the IFNγ in a sample, especially if the starting concentration of IFNγ 
in the sample was high (unpublished observations).The residual amount of IFNγ in the sample 
after a single neutralization step might be still high enough to display considerable antiviral 
effects. Thus, incomplete removal or inactivation of IFNγ from the culture supernatants might 
explain the requirement for STAT1 and the activation of IRF1 observed by Chang et al [165]. 
Using a serial incubation strategy on IFNγ antibody-coated ELISA plates, to deplete IFNγ 
consistently by more than 90% (Table 4-2), we were able to show that IFNγ-depleted CAFprimary 
did not require STAT1 for its suppressive ability (Figure 13 B). The residual IFNγ in these 
samples was too low to affect suppression (data not shown). 
 
However, our results also show that IFNγ may not be the sole reason for the differences 
in STAT1 requirement seen between CAFtransformed and CAFprimary. We found that IFNγ-depleted 
CAFtransformed samples still require STAT1 for efficient suppression of gene expression from a 
transfected LTR-luciferase reporter (Figure 13 A). So while IFNγ might certainly be a 
confounding presence in CAFtransformed, leading to misinterpretations about the role of STAT1 
phosphorylation and the requirement for Jak1 and Jak2, and might explain the activation of  
IRF1 observed by Chang et al., it is only one of possibly many factors that differ between 
CAFtransformed and CAFprimary. 
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An interesting result, which might provide another reason for the differences seen 
between this paper and the findings by Chang et al., is the response of TZM-bl cells to IFNγ and 
IFNγ- depleted supernatants.  IFNγ is known to suppress HIV LTR driven transcription in HeLa 
based cell lines [194, 241]. Our studies indicate that TZM-bl cells are sensitive enough to IFNγ 
that removal of IFNγ from CAFtransformed abolished suppression of viral transcription. Evidence 
for differences in the response of TZM-bl cells and PBMCs was recently presented in a study 
that showed LPS, which exhibits potent anti-HIV activity in PBMCs by inducing the expression 
of beta chemokines, has no effect on TZM-bl cells. Yet culture supernatant from LPS stimulated 
PBMCs exhibited potent suppression of HIV transcription in TZM-bl cells due to the effect of 
PBMC-secreted IFNγ, rather than any beta chemokines [241]. This study, like ours, suggests the 
higher sensitivity of TZM-bl to IFNγ than to other inhibitory factors.  
 
A caveat in our results is that we used the culture supernatant from only one HVS-
transformed CD8+ T cell line in our investigations. It is possible that other HVS-transformed 
CD8+ T cell lines secrete less IFNγ into the supernatant. Indeed, Chang et al did find variations 
in the levels of IFNγ between different transformed CD8+ T cell lines. However, our results from 
the primary CD8+ T cells from 9 HIV-1 infected patients clearly demonstrate a non-IFN γ 
component for CAF, which signals in a STAT1 independent manner.  
 
There have been many soluble factors described since the discovery of CAF, which 
display noncytolytic suppressive activities [130, 132, 242-244]. Some of these factors, like 
prothymosin alpha or HIV Resistance Factor (HRF) identify with CAF in that they too suppress 
viral transcription [132, 243]. But neither of these proteins display the other key characteristics 
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associated with CAF: prothymosin alpha acts on infected macrophages, and not CD4+ T cells, 
while HRF is a factor secreted by CD4+ T cells, and not CD8+ T cells. CAF is thought to be 
secreted in small quantities into the extracellular medium by CD8 + T cells. This has made the 
investigations of CAF, particularly the elucidation of its molecular identity, difficult. 
Transformed CD8+ T cells allow for the production of CAF-containing supernatants in quantities 
not attainable by primary CD8+ T cell cultures.  However, our results suggest that the differences 
between transformed and primary CD8+ T cell culture supernatant are large enough to result in 
misinterpretations.  
 
Proteomic analysis using increasingly versatile mass spectrometery techniques may help 
in both identification of the components of CAF, as well as unravel the different mechanisms of 
viral transcription suppression. In applying such methods, an expanded phosphoproteome 
analysis might aid identification of novel pathway markers for CAF-induced signaling. Hence, 
we examined the phosphorylation status of 10 different proteins, known to be either directly 
involved in the transcriptional regulation of HIV-1 (such as PI3K, PLCg2, JNK, p38 MAPK and 
IL15), or were components of pathways that could regulate viral transcription (such as FRS-2, 
Crk, Tec kinase, Jak3 and STAT3). We found no consistent increase in phosphorylation of any 
of these proteins at 4 different time points after addition of 3 different sources of CAFprimary to 
infected CD4+ T cells. It indicates that either none of these 10 proteins are involved in 
suppression, or that we were not able to capture a phosphorylation event of some of these 
proteins using our methodology. 
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Our studies also suggest that CAF might well be multifactorial: different cytokines and 
chemokines might act in concert to suppress viral transcription and replication. Perhaps there is 
an additive, or even a synergistic, effect of the smaller suppressive abilities of individual 
cytokines, like IFNγ, or chemokines. Investigations of the region of the viral promoter necessary 
for transcription suppression and the proteins that bind to it in the presence and absence of CAF 
may also yield clues to the signaling pathways that suppress viral transcription.  
 
In the last specific aim, we determined the region of the promoter necessary for 
transcriptional suppression of HIV-1 by CAF. While the precise mechanism by which CAF 
inhibits HIV-1 transcription from the LTR is currently unknown, there are various ways by 
which the viral RNA produced from the integrated proviral promoter could be reduced upon the 
addition of CAF to the infected cell.  These may include degradation of viral mRNA in the 
cytoplasm by RNA interference (RNAi) mechanisms, changes in the mRNA export from the 
nucleus or changes in transcription factor (TF) binding at the promoter. Other studies have 
shown that the first possibility, that of mRNA degradation in the cytoplasm by Dicer and 
Drosha-mediated RNA interference, is not likely in the mechanism of CAF action, since siRNA 
treatment against Dicer and Drosha does not inhibit CAF activity [245]. While there are many 
viral proteins, such as influenza NS1 protein, which could act by inhibiting RNA export from the 
nucleus, there has been no evidence to indicate this to be a key method of CAF action  [246]. 
Hence, we focused our attention on the third possibility, namely, alterations in the binding of 
transcription factors to the viral promoter leading to inhibition of transcription. We hypothesized 
that CAF could trigger a signal cascade which culminates by changing the binding of 
transcription factors on the viral promoter, leading to a decrease in transcription efficiency.  
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Our results using the progressively deleted constructs of the HIV-1 LTR indicate that 
each deletion affects transcription of the LTR, because of the loss of various transcription factor 
binding sites (negative or positive regulators) and enhancers that are required for optimal 
transcription from the HIV-1 LTR. However, despite these differences in the level of 
transcription from these constructs, CAF was able to suppress transcription from all of the 
constructs. Data from these 5’ LTR-deletion and TAR deletion constructs indicate that the HIV-1 
minimal promoter consisting of the 3 SpI sites and TATA box is required for CAF mediated 
transcriptional suppression. Moreover, the requirement for 3SpI-TATA region for transcriptional 
suppression is confirmed by demonstrating transcriptional suppression of a promoter-less 
reporter gene construct carrying only these sites without TAR or any other upstream or 
downstream elements.  
 
There are viral promoters that do not respond to CAF-mediated suppression of 
transcription. Among these is the early SV40 promoter, whose minimal promoter also consists of 
SpI sites, in addition to the TATA box (unpublished data from our lab). We attempted to insert 
the HIV-1 3SpI-TATA segment into the SV40 promoter to seek a conversion from CAF-
resistance to CAF-susceptibility of the chimeric promoter. However, the chimeric promoter was 
transcriptionally inactive. Transcription from the SV40 promoter is known to be critically 
dependent upon the 6 SpI sites. Mutation of even one of the SpI sites in the minimal promoter 
region of SV40 is known to significantly decrease transcription. It is possible that the HIV SpI-
TATA was not enough to compensate for the loss of the 6 SpI sites of SV40.  
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It is interesting to speculate about the various ways by which CAF might suppress 
transcription from the LTR region encompassing 3 SpI sites and TATA box. CAF has been 
shown to be equally effective against all HIV-1 clades. If its target on the LTR is indeed the 
minimal promoter, then it is likely that the sequence of the 3SpI-TATA segment is relatively 
conserved among all the clades. We aligned the sequences of the minimal promoter of HIV-1 
Clades A1, A2, B, and C (Figure 34) and observed some differences in the SpI sequences 
between the different clades, although the sequence of the TATA box was conserved. 
 
 
 
 
 
  
 
Not shown here are the sequences of the minimal promoters of HIV- 2 and SIV, against 
which CAF, from the CD8 cells of baboons and chimpanzees respectively, has shown to be 
active.  Both HIV-2 and SIV contain 4 SpI sites upstream of the TATA box. The SpI sites of the 
Ref     CGA----GCTTGCTACAAGGGACTTTCCGCTGGGGACTTTCCAGGG-AGGCGTGGCCTGG 57 
A2      AGA----AGTTGCTGACGGGGACTTTCCGCTGGGGACTTTCCAGGG-AGGTGTGGTGTGG 81 
B       CGA----GCTTGCTACAAGGGACTTTCCGCTGGGGACTTTCCAGGG-AGGCGTGGCCTGG 90 
A1      ----------------------CTTTCCGCTGGGGACTTTCCAGGGGAGGTGTGGTTTGG 125 
C(ETH)    GGG----ACTTTCCGCT-GGGACTTTCCACTGGG--CGTTCCAGG--AGGTGTGGTCTGG 59 
C(IN)     AGACGGGACTTTCCGCC-GGGACTTTCCACTGGGG-CGTTCCAGG--AGGAGGGGTCTGG 176 
          *       ** *     ********** *****  * *******  *** * **  *** 
 
            
Ref    GCGGGACTGGGGAGTGGCGAGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGT 117             
A2     GCGGAGTTGGGGAGTGGCTAACCCTCAGATGCTGCATATAAGCAGCTGCTTCTCGCATGT 141                  
B      GCGGGACTGGGGAGTGGCGAGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGT 150 
A1     GCGGAGTTGGGGAGTGGCCAACCCTCAGATGCTGCATATAAGCAGCTGCTTTTCGCCTGT 185 
C(ETH)   GCGGGACTGGG-AGTGGTCAACCCTCAGATGCTGCATATAAGCAGCTGCTTTTCGCCTGT 118 
C(IN)    GCGGGACTGGG-AGTGGCCAACCCTCAGATGCTGCATATAAGCAGCTGCTTTTCGCTTGT 235 
        ****   **** *****  * ********* ******************** * ** *** 
Figure 34: Alignment of minimal promoter region of HIV-1 Clades A1, A2, B, and C 
The SpI sites (yellow highlights) and the TATA box (bold letters) of the LTR of single isolates of Clades A1, A2, and 
B and two isolates of clade C were aligned using ClustalW2. Ref refers to the sequence of the construct used in this 
study. A2 refers to the clade A2 isolate 94CY017.41 (Acc no. AF286237), B refers to the clade B HXB2 isolate (Acc 
no. K03455), A1 refers to the clade A1 isolate Q23-17 (Acc no. AF004885), C(ETH) refers to the clade C isolate 
ETH2220 (Acc no. U46016) and C(IN) refers to the  clade C isolate IN21068 (Acc no. AF067155).  
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HIV-1 promoter are crucial for transcription. While SpI has been found to be important for the 
transcription of HIV-2 [247], it is thought to be dispensable for efficient transcription from the 
SIV promoter [248]. Yet, these sites do not just bind the SpI protein. These same sites act as 
recognition elements for other members of the Sp1 family, notably Sp3 and Sp4. While all 
members of the SpI family of proteins have similar structures and affinity for GC-rich sequences, 
their effects on transcription may be different. Sp4 has been shown to have activating effects on 
HIV transcription, similar to Sp1, whereas Sp3 competes with Sp1 for the same binding sites and 
represses transcription from the LTR [249]. It is possible that CAF, through the induction of 
some intermediate protein, promoters the binding of Sp3, over Sp1, to the HIV minimal 
promoter. Recent studies with chromatin immune-precipitation (ChIP) have shown that the 
proteins SpI, c-myc and HDAC1 form a complex at the HIV promoter, which represses 
transcription from the viral promoter and promotes latency [240]. The tumor suppresser and cell 
cycle protein p53 has been shown to bind SpI and repress transcription from the HIV LTR [250].  
CAF might function by facilitating one of these processes.  
 
CAF might also directly affect the TATA box, by adversely impacting one of the many 
proteins that constitute the transcription pre-initiation complex.  The TATA box serves as the 
recognition element for the TATA box binding protein, TBP, which is a component of the 
general Transcription Factor TFIID. TFIID, through TBP, associates with the TATA box and in 
turn, recruits many other transcription initiation factors, known as TBP Associated Factors or 
TAFs to the site. Following the binding of TFII, TFIIB and RNA polymerase associate with the 
promoter, and then TFIIA, TFIIIE, and TFIIH follow. Thus, the initiation of transcription in 
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eukaryotic cells is a complex process and CAF might interrupt at any of these stages, leading to 
transcriptional repression. 
Earlier studies to identify the region on the LTR necessary for CAF activity had 
suggested that multiple transcription factor binding sites may play a role in transcriptional 
suppression and had highlighted the importance of NFKB and the transcription factor 
NFAT/COUP-TF within the NRE in the suppressive process [251]. While our results provide 
further evidence for the multi-pronged nature of CAF action on the LTR, we found no 
requirement for NFKB or NFAT/COUP-TF for the action of CAF. To our knowledge, ours is the 
first study to identify the minimum target site on the LTR that is sufficient for transcriptional 
suppression.  
 
Our studies show that the minimal region of the LTR that is necessary for CAF-mediated 
transcriptional suppression involves the 3 SpI sites and the TATA box, a region 90bp long. 
Complex and stochastic interactions between the proteins that bind this region can switch the 
balance between activation and inhibition of transcription, as other papers have shown [252-
254]. A small change in the ratio of activating complexes, consisting of Histone 
Acetyltransferases (HATs), to repressing complexes, consisting of Histone Deacetylases 
(HDACs), can shift the balance from transcription activation to transcriptional suppression [252]. 
Thus, it is possible that CAF action on the target cell leads to protein modifications, such as 
deacetylation, on the LTR that tip the balance towards transcriptional suppression. 
 
The story of CAF is intriguing because of its many implications. The study of 
transcriptional suppression by CAF may shed light on mechanisms of HIV-1 latency. HIV-1 
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LTR is associated with 5 precisely positioned nucleosomes, named nuc0 to nuc 4 [255]. It has 
been shown that one of these nucleosomes of the HIV-1 LTR is immediately downstream of the  
3 SpI sites and TATA box, which are the targets of CAF. Latency of HIV-1 has been shown to 
be associated with the presence of deacetylated histones at these nucleosomes.  If CAF 
suppresses gene expression from the LTR by recruiting histone deacetylases to this region, its 
mechanism of action may be similar to some of the events taking place during HIV-1 latency. 
The removal of CAF eventually leads to resurgence in viral replication. The events taking place 
at the LTR during this process might mirror those taking place during reactivation of virus after 
latency.  
 
CAF is a host cellular factor that can suppress HIV-1 transcription. It is secreted by CD8 
T cells, key players of the adaptive immune system, but does not appear to require either antigen 
presence [183, 256] or MHC restriction, displaying characteristics of an innate immune signaling 
protein. Hence, CAF might be a bridge between the adaptive and innate arms of the immune 
system. Activity of CAF has been found active against FIV and SIV, which infect cats and non-
human primates respectively. Although there have been no studies looking at the effect of CAF 
on Equine Infectious Anemia virus (EIAV), the counterpart of HIV in horses, or on Caprine 
Arthritic Encephalitis Virus (CAEV), the counterpart of HIV in goats, it is possible that these 
animals have similar responses too. Perhaps CAF evolved as a mechanism in mammals to 
repress gene expression from retroviruses. Nearly 8% of the human genome is made of human 
retroviral elements [257]. A recent paper demonstrated that the expression of human endogenous 
retroviral (HERV) elements was no longer silenced in HIV-1 infected cells. The authors 
demonstrated that HIV-1 induced active transcription of genes from endogenous retroviral 
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promoters, leading not only to the production of HERV proteins, but also to the activation of 
HERV-specific CD8 T cells [258]. Certainly it is possible that there are host restriction factors 
which suppress not only the endogenous retroviral elements, but also invading retroviruses. 
There is already a precedence for a host restriction factor which has evolved to silence the 
expression from endogenous retroviral elements, while also displaying potent suppressive 
activities on HIV-1: APOBEC-3G, from humans, African Green Monkeys (AGM) and mice, has 
been shown to inhibit the gene transposition of two active murine retroviruses  [259]. CAF might 
well be a second factor or a group of factors for the same purpose.  
 
In conclusion, our results suggest that CAF acts by triggering a signal transduction 
cascade within the target cells, and acts on the 3 SpI-TATA segment of the HIV-1 LTR to effect 
suppression from the viral promoter.   
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8.0  FUTURE WORK 
Determination of alterations to protein binding on the HIV LTR in response to CAF: 
We have identified a minimal region on the HIV LTR that is necessary for CAF action. 
This region consists of the 3 SpI sites and TATA box. Using ChIP assays combined with Mass 
spectrometry, it will be possible to identify the exact proteins binding to this region, upon 
exposure to CAF. Once these proteins have been identified, their upstream binding partners and 
regulators of activation can be identified. Then these proteins, in turn, can be examined for their 
role in the CAF-mediated suppressive process. 
 
Identification of signaling cascades in cells treated with CAF, by tracking phosphorylation 
patterns:  
Another method to identify signaling cascades involved in the HIV transcriptional 
suppression process in cells treated with CAF is by mass spectrometry. Mass spectrometry of 
protein lysates from cells treated with CAF might be able to identify proteins that are being 
specifically phosphorylated in response to the treatment. Phosphorylation is probably the most 
common method of intracellular signal transduction. Hence it is possible that CAF activates 
some phosphorylation cascades within the target cell, even though our method using antibody 
coated beads could not detect these.  Once a list of these proteins is obtained, they will then be 
examined for their role in the transcription suppression process.  
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Identification of “CAF-Resistant” cell lines to determine proteins that confer 
resistance/susceptibility to CAF: it is possible that there are cell lines in which HIV transcription 
does not get suppressed in response to CAF. In fact, TZM-bl cells, themselves, might be a 
possible candidate for this phenotype, since they show no suppressive ability when treated with 
IFNγ-depleted cultures. Once a cell line is identified that consistently shows no suppression in 
response to CAF treatments, gene transfer experiments may be performed to identify specific 
genes or gene products that are necessary for conferring susceptibility to CAF.  
 
The relationship between Regulatory T cells and CAF production by CD8 T cells as a 
possible method to identify CAF : CAF activity has been shown to correlate with clinical status 
of disease. For instance, CD8 cells from patients who are in the acute stage of infection are better 
able to suppress HIV transcription than those from patients who are in the stage of AIDS. While 
it is understandable that CD8 cells from patients who are at a more advanced stage of disease are 
likely to be dysfunctional due to a variety of reasons (some of which are detailed in the 
Introduction section), perhaps it is possible that the state of activation of the cell also has 
something to do with the ability to mediate viral suppression by CAF.  Many studies have shown 
that non-pathogenic SIV infection in AGMs, Sooty Mangabeys and chimpanzees is associated 
with a lack of hyperactivation of the immune system, in contrast to what is seen in humans or 
rhesus macaques. Indeed, chronic activation of the immune system appears to be one of the 
crucial prognostic markers for disease progression in humans.  
Regulatory T cells have been shown in asymptomatic, healthy HIV-1 infected individuals 
to significantly lower plasma viremia, play a role in maintaining high CD4+:CD8+ T cell ratios 
and are favorable clinical markers of disease status. In vitro, they are known to suppress cellular 
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proliferation and cytokine production by CD4 and CD8 T cells [260]. Treg depletion has also 
been known to be associated with higher levels of cellular activation in infected subjects [261].  
 
It would be interesting to determine if CD8 cells from patients in the chronic stage of 
HIV regain CAF activity in vitro if the cells were co-cultured in the presence of regulatory T 
cells. If they do, further experiments could be performed to find out which genes, activated in 
these CD8 T cells in response to the Tregs, are responsible for the production of CAF. These 
experiments might take us closer to finding out the identity of CAF, and indeed, if CAF is a 
multi-factorial or a single protein.  
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APPENDIX 
LIST OF DNA OLIGONUCLEOTIDES AND PRIMERS TO CREATE SP1 DELETION 
MUTATIONS AND INACTIVATING POINT MUTATIONS 
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SpI deletion construct oligos and primers 
 
 
 
 
 
 
 
 
 
 
 
 
 No 
Name of 
construct 
DNA oligos used PCR primers 
1 
 
Del 1, del 2 
5’TCGGAGGACAGTACTCCGACCCGGTCGAAG
GGAGGCGTGGCCTGAGCCCTCAGATCCTGCAT
ATAAGC 
And 
5’GAGCCCTCAGATCCTGCATATAAGCAGCTG
CTTTTTGCCTGTACTGGGTCTCTCTGGTTAGAC
CAGATCCGAGC 
 
Fwd:TGTGAAGCTTTCGGAGG
ACAGTACTC 
Rev:TGTGGAGCTCGGATCTG
GTCTAAC 
2 
 
Del 1 
5’TCGGAGGACAGTACTCCGACCCGGTCGAAG
GGAGGCGTGGCCTGGGCGGGACTGAGCCCTC
AGATCCTGCATATAAGC 
                                              And 
5’GAGCCCTCAGATCCTGCATATAAGCAGCTG
CTTTTTGCCTGTACTGGGTCTCTCTGGTTAGAC
CAGATCCGAGC 
Same as above 
3 
 
Del 2 
5’TCGGAGGACAGTACTCCGACCCGGTCGAAG
GGAGGCGTGGCCTTGGGGAGTGGCGAGCCCT
CAGATCCTGCATATAA 
And 
5’GAGCCCTCAGATCCTGCATATAAGCAGCTG
CTTTTTGCCTGTACTGGGTCTCTCTGGTTAGAC
CAGATCCGAGC 
 
Same as above 
  
 Sp   3     2      1 
TATA 
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SpI inactivating point mutation oligos and primers 
 
 
 
 
Name of 
construct 
DNA Oligos used Primers used 
Mut 1 Oligo 1: 
TCGGAGGACAGTACTCCGACCCGGTCGAAGGGAGGCGTGGCCTG
GGCGGGACTGGTTAGTGGCGAGCCCTCAGATCCTGCATATAA 
 Oligo 2:  
GAGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACT
GGGTCTCTCTGGTTAGACCAGATCCGAGC 
Fwd:TGTGAAGCTTTC
GGAGGACAGTACTC 
Rev:TGTGGAGCTCGG
ATCTGGTCTAAC 
Mut 2 Oligo 1: 
TCGGAGGACAGTACTCCGACCCGGTCGAAGGGAGGCGTGGCCTG
TTCGGGACTGGGGAGTGGCGAGCCCTCAGATCCTGCATATAA 
 Oligo 2: same as above 
Same as above 
Mut 3 Oligo 1: 
TCGGAGGACAGTACTCCGACCCGGTCGAAGGGATTCGTGGCCTG
GGCGGGACTGGGGAGTGGCGAGCCCTCAGATCCTGCATATAA 
Oligo 2: same as above 
Same as above 
Mut 1, 2 Oligo 1: 
TCGGAGGACAGTACTCCGACCCGGTCGAAGGGAGGCGTGGCCTG
TTCGGGACTGGTTAGTGGCGAGCCCTCAGATCCTGCATATAA                                                     
 Oligo 2: same as above 
Same as above 
Mut 1, 3 Oligo 1: 
TCGGAGGACAGTACTCCGACCCGGTCGAAGGGATTCGTGGCCTG
GGCGGGACTGGTTAGTGGCGAGCCCTCAGATCCTGCATATAA 
Oligo 2: same as above 
Same as above 
Mut 2, 3 Oligo 1: 
TCGGAGGACAGTACTCCGACCCGGTCGAAGGGATTCGTGGCCTG
TTCGGGACTGGGGAGTGGCGAGCCCTCAGATCCTGCATATAA 
 Oligo 2: same as above 
Same as above 
  
 Sp   3     2      1 
TATA 
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